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SUMMMARY 
The evaluation of the potential to use Ultra Performance Liquid Chromatography 
(UPLC) for the simultaneous quantification of all the actives in a multi-active tablet is 
described in this work. Part of the evaluation was to ensure that the necessary 
regulatory requirements were adhered to by ascertaining that an analytical method is 
suitable for a specific purpose through analytical method validation for the specific 
multi-active tablet. 
The UPLC method was also tested for the analysis of similar products, namely tablet 
formulations that contain similar active ingredients in the same proportions but with an 
additional active ingredient. 
A method for the simultaneous determination of paracetamol, caffeine and codeine 
phosphate was developed using UPLC technology. The UPLC developed method 
was more efficient than the existing in-house HPLC method. The UPLC method was 
then validated in accordance to ICH and USP guidelines.  
The application of this UPLC method for the analysis of similar products containing 
paracetamol, caffeine, codeine phosphate and one extra active ingredient was very 
challenging. The low concentration of the additional component, differences in sample 
matrix and differences in formulations added to the challenges. The direct application 
for the analysis of products Y and Z was not successful; however the method could be 
used as a platform for further research.  
A cost comparison between the UPLC and HPLC methods showed the UPLC method 
to be more cost effective. Thus, while maintenance costs are higher for the UPLC 
instrument, column costs are comparable to HPLC columns, but solvent and waste 
disposal charges decrease considerably due to lower solvent use. The reduction in 
instrument time dramatically improves the cost effectiveness of UPLC over HPLC due 
to a concurrent reduction in analyst time requirement.  
The results of this study show that the analytical costs associated with the analysis of 
multi-active drugs using HPLC procedures can be reduced substantially by the 
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implementation of UPLC technology. The hypothesis that the enhanced 
chromatographic power of UPLC can be leveraged to provide faster analysis times 
hence increased product throughput rates, and lower operating costs for the analysis 
of multi-active drugs was accepted. These advantages were achieved whilst meeting 
all regulatory requirements for analytical methods as required by regulatory bodies. 
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CHAPTER 1: INTRODUCTION 
1.1 PROJECT BACKGROUND 
Pharmaceutical companies generally have to spend substantial amounts of money on 
research, development, and regulatory requirements to bring new drugs onto the 
market and to keep existing products on the market. The establishment of a 
substantial global generic drug industry is an attempt to make pharmaceutical 
products more affordable by producing drugs that are no longer protected by patents. 
Due to the highly competitive nature of the generic pharmaceutical industry, 
companies must constantly seek economic advantages through cost reduction, 
including the cost of raw materials and manufacturing costs by optimization of 
manufacturing and testing processes. 
This project is specifically concerned with an evaluation of the potential reduction of 
medium- to long-term costs of HPLC analytical procedures for the analysis of multi-
active drugs in Aspen Pharmacare by evaluating the suitability of UPLC as alternative 
to HPLC. 
Testing procedures include analysis of starting materials, in-process analyses, and 
analysis of finished goods, and include both qualitative (e.g. identification of raw 
materials) and quantitative analysis (testing of active substance concentration in final 
product). Common types of testing methods include wet chemistry, infra-red 
spectrophotometry, ultraviolet spectrophotometry, and chromatographic methods. 
Chromatography is the collective term for a set of laboratory techniques used for the 
separation of mixtures into its individual components, 1 followed by identification and 
quantification of each individual component. 
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1.2 PROBLEM STATEMENT 
High performance liquid chromatography is the major analytical technique used in 
Aspen Pharmacare’s analytical divisions for the analysis of active components in 
finished pharmaceutical products. Despite the introduction of 24–hour shift operations 
in analytical laboratories, analysis of finished products remains the bottle-neck in the 
supply chain. The use of HPLC analytical methods is a main contributor due to the 
long analysis times associated with HPLC analysis. In addition, HPLC analysis has 
also become expensive, in part due to the use of relatively large volumes of analytical 
grade solvents, and in part due to operator costs. 
1.3 A BRIEF HISTORY OF LIQUID CHROMATOGRAPHY 
The Russian botanist, Tswett1, first discovered adsorption chromatography in 1903. 
His experiment consisted of the separation of pigments in green leaves using calcium 
carbonate as packing material in glass columns. The separated species formed 
various coloured bands on the columns. From these experiments, the word 
chromatography was derived from the Greek word “chroma” meaning colour and 
“graphein” meaning to write.1 Chromatography is now the collective term for a set of 
laboratory techniques for the separation of mixtures before detection by an 
appropriate technique. (The most commonly used detectors in the pharmaceutical 
industry are the Ultra Violet (UV), Refractive Index (RI) and the Photo-diode Array 
detector (PDA).) 
In 1938 the technique of chromatography was first used for the separation of 
petroleum fractions. In 1941 Martin and Synge2 predicted the use of gas as mobile 
phase in gas liquid chromatography and the use of small particles as packing together 
with high pressures in high performance liquid chromatography. As a result their work, 
the techniques of chromatography developed substantially during the 1940’s and 
1950’s.2  
In 1958 Ismailov and Schradiber performed the first experiments using thin layer 
chromatography (TLC).3,4  Thin layer chromatography is carried out  on a sheet of 
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glass which is coated with a thin layer of absorbant material, known as the stationary 
phase, normally sillica gel or cellulose. After the sample has been applied onto the 
plate, it is placed in an enclosed tank containing a small amount of mobile phase. The 
mobile phase is drawn up the plate via capillary action.  
The analytes are separated into various bands due to the different interaction of each 
analyte and the stationary phase. Up to the early 1960’s most chromatographic 
separations were carried out using techniques such as paper chromatography and 
thin layer chromatography. For the quantification of compounds as well as the 
resolution of similar compounds these techniques was found to be ineffective.3 
1.3.1  HIGH PERFORMANCE LIQUID CHROMATOGRAPHY-HPLC 
In 1962, pressure was first used to force liquid through a column containing a packing 
material to effect separation between different compounds. The use of high pressures 
decreased flow–through time through the column, therefore decreasing the overall 
separation time of the compounds. This initial work led to the development of the first 
modern high-performance liquid chromatography (HPLC) system in 1965 (accredited 
to C Horvath).3  
Normal-phase chromatography is a mode of liquid chromatography where the 
stationary phase is polar (for example silica) and the mobile phase is non-polar 
(normally mixtures of chloroform, hexane, and isopropanol). Reverse-phase 
chromatography is a mode of liquid chromatography where the stationary phase 
consists of non-polar polymeric chains bonded onto a silica base (for example C8 and 
C18) and the mobile phase is polar, for example mixtures of water, methanol and 
acetonitrile. Reverse-phase chromatography is widely used in the pharmaceutical 
industry due to its versatility, low solvent toxicity and relatively low cost.5 Reverse-
phase liquid chromatography also allows for the separation of very similar 
compounds. 
The following flow scheme (Figure 1.1) illustrates the basic components of HPLC 
namely the solvent/s (mobile phase), pumping system, injector (sample manager) 
column (stationary phase), detector and processing station. 
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Figure1.1: Schematic representation of the High Performance Liquid 
Chromatography system.
 
Some Applications of HPLC
HPLC can be applied to both qualitative and quantitative analyses. In the 
pharmaceutical industry there are two major types of quantitative analysis: assay and 
dissolution. 
In molecular biology, an assay is defined as a procedure for 
activity of a drug or biochemical of organic origin. The term can also describe the 
quantitative determination of an analyte in a sample.
Dissolution is simply a process by which a solid substance dissolves and can be 
measured by the change in solute concentration.
monitored in vivo through measurement of their concentrations in plasma or urine in a 
human subject. The obvious impracticalities of applying this technique routinely have 
culminated in the introduction of official 
comprehensively defined in the respective Pharmacopoeias. The concepts and 
instrumentation associated with drug dissolution testing are briefly outlined below.
“Tablet dissolution” is a standardized method for quantifying the rate of drug release 
from a dosage form. The objectives of this test can be summarized as follows:
5
 
 
testing or measuring the 
 6
 
 7,8 
 Drug pharmacokinetics can be 
in vitro dissolution tests. Such tests are 
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• Optimization of therapeutic efficacy during product development and stability 
testing 
• Assuring uniformity between 
production quality
• Evaluation and assurance of bioequivalence, i.e. production of identical 
biological availability, in discrete batches of product from one or different 
manufacturers 
• Prediction of drug bioavai
There are four major types of 
specified by the United State
• USP Dissolution Apparatus 1 
• USP Dissolution Apparatus 2 
• USP Dissolution Apparatus 3 
• USP Dissolution Apparatus 4 
Figure 1.2:  Automated 
production lots through routine assessment of 
 
lability (in vivo)9 
dissolution apparatus that are standardized and 
s Pharmacopoeia (USP). These include
- Basket  
- Paddle  
- Reciprocating Cylinder  
- Flow-Through Cell  
USP Dissolution Apparatus 2 
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Of the above, USP dissolution apparatus 2 is the most widely used (illustrated in 
Figure 1.2) and is also used during this study. 
1.3.2  ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY-UPLC 
HPLC users have continually required new and improved ways to increase 
throughput. Column developers have answered to these needs by developing more 
efficient and more reliable packing materials, including packing materials with reduced 
particle size. The following Table 1.1 illustrates the development in particle size 
technology for liquid chromatography. 
Table 1.1: The development in particle technology for Liquid Chromatography10 
 
 
 
Research during the past decade has focused on column chemistry with the aim of 
providing faster and improved separations of more complex mixtures. Column 
chemistry has seen changes in particle size,  particle shape and the type of packing 
Year(s) of Acceptance 
 
Most Popular 
Nominal Size 
≈ Plates/15 cm 
1950’s 100 µm 200 
1967 50 µm 1 000 
1972 10 µm 6 000 
1985 5 µm 12 000 
1992 3 - 3.5 µm 22 000 
1996* 1.5 µm (pellicular) 30 000 
1999 5.0 µm (poroshell) 8000 
2000 2.5 µm 25 000 
2003 1.8 µm 32 500 
 CONFIDENTIAL INTELLECTUAL PROPERTY OF ASPEN PHARMACARE Page 14 
 
material, for example a decrease in size from 10 µm to 2 µm, particle shape from 
irregular particles to regular spherical particles, and from inorganic silica to hybrid 
particles. Hybrid particles combine the inorganic (silica) and organic (polymeric) 
packing to produce a material which has high mechanical strength and high pH 
stability. This provides columns with better selectivity and improved column efficiency. 
Mechanical strength is the physical strength of the packing material that allows 
columns to withstand high pressures. Normal silica packing material has a pH range 
of 2 – 8, whereas hybrid particles packing materials have a pH range of 1 – 12. This 
pH range allows for more flexibility in method development. 
Chromatographic resolution, or separation power, can be defined as the degree by 
which two compounds are separated [RS]. Two principal factors which determine the 
overall separation power of an HPLC column are mechanical separation power and 
chemical separation power.11 Mechanical separation power is determined by the 
column length, particle size, and uniformity of the packed-bed (for example both a 
longer column, and a column containing smaller particles increase the separation 
power). This is measured by the column efficiency. Chemical separation power is 
determined by the physicochemical interactions between the compounds in the 
mobile phase and the packing material. This is measured by the column’s selectivity. 
Smaller-particle columns have higher efficiency, but operate at higher back pressures 
(pressure drop across a column). If the particle size is kept constant, the length of 
column must be increased to obtain a higher efficiency (Figure 1.3). There is, 
however, a limit of how long columns can be made. These limits are influenced by 
longer chromatographic run times, greater solvent consumption, and higher operating 
back pressures. Shorter column lengths are advantageous in these respects, but 
mechanical separation power is generally reduced (Figure 1.4).11 
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Figure 1.3:  Illustration of the effect of Column Length on mechanical separating 
power (constant particle size)11 
 
Figure1.4:  Illustration of the effect of particle size on mechanical separating power 
(constant column length).11 
 
There are several potential advantages associated with using smaller particles in 
liquid chromatography columns. These include: The column length can be shortened 
without reducing the plate count; faster separations as separation time is directly 
proportional to the length of the column; and reduced operating costs by using less 
mobile phase (a shorter column can be run at the same linear velocity of mobile 
phase as a longer column and as a result use less solvent).10 
The primary disadvantage associated with the sub-2 µm particle size packing 
materials is an increase in the system operating backpressure, that increases up to 15 
000 psi compared to a backpressure of around 4 000 psi for traditional HPLC. 
Analytical systems equipped to operate at these pressures have been developed and 
are known today as ultra performance liquid chromatography or UPLC.12 
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Column efficiency is often measured 
N] of a column. Since column efficiency is inversely proportional to the particle size
the column packing, higher column effic
particle size.13 This relationship
equation. 
H.……the height of the theoretical plate in 
u……..the linear velocity of the mobile phase in 
B…….the longitudinal diffusion, the rate of migration from an area of high 
concentration to an area of low concentration. In a column this would be from 
the centre to the more dilute areas, the outer regions.
Cs/Cm are coefficients of mass
(eddy diffusion). 
The Van Deemter plot as show
linear velocity of the mobile phase and plate height (column efficiency). 
Figure 1.5:  Van Deemter Plot
as the number of the theoretical plates [symbol = 
iencies can be achieved 
 is represented by Equation 1.1
       											1.1 
centimetres 
centimetres per second
 
-transfer in the stationary phase and the mobile phase 
n in Figure 1.5 illustrates the relationship between 
 
14 
 Page 16 
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by decreasing 
, the Van Deemter 
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Steward (Waters Corporation) describes the relationship between particle size and 
efficiency in terms of resolution3. “Since efficiency (N) is inversely proportional to 
particle size	 = 

, the reduction in particles size from 5 µm to less than 1.7 µm 
means efficiency is increased by three times”. This reduction in particle size comes at 
a cost since smaller particles increases the back pressure of the system (pressure 
drop across a column), especially at higher flow rates.  
Waters, one of the manufactures of the first UPLCs, claims that chromatographic 
method development becomes much faster, that analysis times will be reduced, that 
the system is more cost effective in terms of solvent usage and production of less 
waste, and that this system is environmentally friendly.15 UPLC in a nutshell presents 
the scientist with new potential to expand the use of this separation technique by 
increasing the speed, resolution and sensitivity of the data acquired.”16 
1.3.2.1 UPLC THE PARTICLE TECHNOLOGY 
Many HPLC column particles do not possess the mechanical stability and structural 
integrity to withstand UPLC operating pressures of around 15 000 psi. In 1999 as 
listed in the brochure,17 Waters launched its first generation hybrid particle technology 
(HPT). HPT combines the properties of inorganic (silica) and organic (polymeric) 
packing to produce a material that has superior mechanical strength and high pH 
stability. HPT materials are essentially poly-ethylsiloxane particles (Figure 1.6) with 
the ethylsiloxane bridges both on the surface and throughout the body of the material. 
These particles show a broad range of chemical stability over a wide pH operating 
range (pH 1 – 12), thus minimizing the interactions of the matrix with any analyte 
functionalities.18 
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Figure 1.6:  Illustration of the poly-ethylenesiloxane structure.19 
 
1.3.2.2  UPLC INSTRUMENTATION  
The basic design of the UPLC is similar to that of a conventional HPLC), consisting of 
four main components:  
a)  Solvent Manager (pumping system), 
b) Sample Manager (sample introductory system),  
c) Column compartment  
d) Detector 
  
 CONFIDENTIAL INTELLECTUAL PROPERTY OF ASPEN PHARMACARE Page 19 
 
 
  
Figure 1.7:  Typical UPLC system 
 
 
 
Detector (d)  
 
Column compartment (c) 
 
Sample Manager (b) 
 
Binary solvent 
Manager (a) 
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a) Solvent Manager (pumping system) 
The pumping system uses a binary pumping system where conventional HPLC uses 
a quaternary pump system. The solvent delivery system compensates for solvent 
compressibility across a wide range of pressures to achieve a smooth and 
reproducible flow for a variety of solvents and using both isocratic and gradient 
operating modes. 
b) Sample Manager (sample introductory system) 
The sample introductory system is automated and the injection process is pulse free. 
The total system or dwell volume is kept small so as to reduce band spreading of the 
injected sample. The system consist of an out-of-flow injector which makes use of 
various injection loops ranging from 2 µl to 10 µl where low volumes can be injected 
accurately with minimum amount of carryover ( when active peaks appear in  injection  
of blank solutions, where no peaks are expected).  
c) Column compartment  
The column chamber is a temperature controlled chamber where the column is 
housed and it allows the column temperature to be regulated. 
d) Detector 
The detector is a Photo-Diode Array (PDA) detector. The PDA detector is a 
specialized UV detector that allows the user to check if separated peaks are “pure” 
during the method development stage. It is important to know that all the peaks of 
interest are separated adequately. For the UPLC, the PDA Detector cell is created 
such that the cell has a minimal dispersion volume to preserve the efficiency of the 
separation. It has a high sampling rate to capture enough data points across a peak to 
perform accurate and reproducible integration of the peak, as peak widths can be less 
than one second. 
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1.4 RESEARCH HYPOTHESIS  
The research hypothesis to be tested during the course of this project is as follows: 
The enhanced chromatographic power of UPLC may be used in the analysis of multi-
active pharmaceutical products to provide faster analysis times, hence increased 
product throughput rates, lower operating costs, as well as provide a method platform 
for the analysis of certain multi-active products. These advantages can be achieved 
whilst at the same time meeting all regulatory requirements for analytical methods as 
required by regulatory bodies. 
1. 5 APPROACH 
The evaluation of UPLC for the simultaneous quantification of all the actives in a 
multi-active tablet will be attempted. Part of the evaluation will ensure that the 
necessary regulatory requirements are adhered to. This will be done by ascertaining 
that the analytical method is suitable for a specific purpose, which will be 
demonstrated by following a set of predetermined guidelines. This process is called 
Analytical Method Validation. 
The evaluated method will also be tested for the analysis of similar tablet formulations 
that contain similar active ingredients in the same proportions but with an additional 
active ingredient that may differ. 
1.6 LEGAL REQUIREMENTS 
The pharmaceutical industry is a highly regulated industry in terms of its practices, 
and requirements are enforced during the manufacturing, testing, release and 
registration of products intended for medicinal use. The main purpose is to safeguard 
and protect the public by ensuring that all medicines that are sold and in use are safe, 
therapeutically effective and consistently meet acceptable standards of quality. There 
are many regulatory bodies internationally: examples of such bodies include the 
United States Food and Drug Administration (FDA), and the United Kingdom Medicine 
and Healthcare Product Regulatory Authority Agency (MHRA).These bodies have 
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different requirements and it is very important for Pharmaceutical manufactures to 
understand these to compete in the global market.  
The standards for testing medicines in the United States is prescribed in a book called 
the United States Pharmacopeia. Similarly, medicines sold in the United Kingdom are 
tested using the British Pharmacopeia (BP) and the European Pharmacopeia (EP). 
These standards describe testing procedures that will ensure that medicines are safe 
and effective by verifying that the manufacture, packing and distribution of medicines 
are performed consistently.   
The standards include test methods for quality, purity and therapeutic effectiveness.  
The quality aspects typically include test methods for identification of ingredients and 
the determination of potential harmful substances that may occur during manufacture 
or during long term storage.  The test methods for purity and strength include the 
active content per dose, known as assay, and the therapeutic effectiveness which 
verify the rate of release of the active drug substance, also known as dissolution 
testing. 
For international markets the regulatory authorities require strict compliance to the 
latest pharmacopeia for analytical testing methods. The USP has a chapter which 
describes changes that can be done to meet system suitability criteria. “The 
prescribed changes may require additional validation data. Making use of the 
adjustments in column length (adjusted by as much as ± 70 %), internal diameter 
(adjusted by as much as ± 25 %), particle size (can be reduced by as much as 50 %) 
and flow rate (adjusted by as much as ± 50 %)”.20,21 While these allowances may 
accommodate the definition of UPLC parameters, any parameters falling outside of 
these allowable changes will require full validation and the method will be seen as 
non-compendial.  
In South Africa the pharmaceutical industry is governed by the stipulations of the 
“Integrated Medicines and Related Substances Act”, Act 101 of 1965 as amended 
and the regulatory body is known as the Medicines Control Council (MCC).22 
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In Act 101, Section 15 describes the process of registration, while sub-section 15 A 
describes the process of amendments to registered products through a guide called 
“Post Registration Amendments”. There are two major classes of amendments 
namely: 
Type A –These are amendments that are unlikely to have an effect on the quality and 
performance of the dosage form and therefore do not require prior approval 
and may be implemented without prior notification. 
Type B - These are amendments that could have a significant impact on the quality 
performance of the dosage form and, therefore, require notification of the 
type of amendment to the MCC 30 days prior to intended 
implementation.23 
A change in the analytical method from HPLC to UPLC will not have an impact on the 
quality of the product; hence a Type A amendment would need to be carried out 
should the findings of this work support such a change. The process of establishing 
the suitability of an analytical method for a specific purpose is termed analytical 
method validation. The MCC has a guide to “Good Manufacturing Practice for 
Medicines” in South Africa24 which has been updated in 2008 to include requirements 
for analytical method validation.25 This guide incorporates guidelines of the 
International Council for Harmonization (ICH) for validation requirements. 
1.6.1  METHOD DEVELOPEMENT PARAMETERS 
For the development of a chromatographic method, a number of criteria must be met 
so as to demonstrate that adequate separation has been achieved. The following are 
a list of the chromatographic criteria to be used for the development of the UPLC 
method: 
• Peak resolution of all peaks, Rs ≥ 2.0: 
Peak resolution (Rs) is defined (W Dolan)22 as a measure of peak separation 
during liquid chromatography. Resolution is expressed mathematically by 
Equation 1.2 and its application illustrated in Figure 1.8: 
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In Eqn [1.2], T2 = retention time of peak
peak in minutes; w
 
Figure 1.8: Measurement of Resolution
When Rs ≈ 1.5, two symmetrical peaks will be completely separated, but
against some deterioration in the separation, most chromatographers select a value of 
1.75 to 2.0 as a minimum acceptance criterion.
• Peak retention factor (
Retention factor (
component resides in the stationary phase relative to the time it resides in the 
mobile phase”.26 
peak and is obtained 
T1 
1,2   
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             [1.2] 
 2 in minutes; T
2 and w1 = widths of peaks 2 and 1 (in minutes), 
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k’) ≥ 1 
k’) is defined as “the period of time that the sample 
It is calculated as the adjusted retention time 
as shown in Equation 1.3 and Figure 1
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In Eqn [1.3], TR = retention time of the analyte
unretained peak.27
Figure 1.9: A measure of retention factor
• Peak tailing ≤ 2 
A peak is labelled as tailing or asymme
symmetrical shape of a Gaussian peak. 
is wider than the front half and the broadening appears to be emphasized near 
the base line.28 
packing sites have a stronger than normal retention 
results in slower desorption kinetics. 
 
It is rare to have a perfectly symmetrical peak shapes
result from injecting excessive amounts of sampl
fittings, excessive detector volume, and slow detector response.
tailing factor is ≤ 1.5, it is not worth trying to improve.
acceptance for peak 
factors to be estimated by Equation 
Tm
TR 
; TM = retention time for an 
 
  
trical when it deviates from the ideal, 
In such cases, the later
Peak tailing is normally due to chemical dis
for
 
 since p
e, badly packed columns, poor 
30
tailing is 2.0. The U.S. Pharmacopeia requires tailin
1.4 as illustrated by Figure 
	
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In Eqn [1.4], Tf = the USP tailing factor
the leading edge to a perpendicular line
the peak height; 
line to the back edge. 
 
Figure 1.10: Measurement of peak tailing using the USP tailing factor, T
from J W Dolan
 
• Column efficiency: The column efficiency 
is a direct measure of the theoretical plates or efficiency which describes peak 
broadening as a function of retention on the column. The U.S. Pharmacopeia 
requires column efficiency to be estimated by Equation 
Where N = the number of theoretical plates
v1 = the distance to the peak of interest (mm) 
w= the peak width at base line determined by tangents
 
Apart from the above, it is preferable that a
preferably close to 5 minutes
 
a
5 % height 
; a = the front half-width measured from 
 dropped from the peak
b = the back half-width measured from the perpendicular 
 
 
)26 
(also called theoretical plate count) 
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1.6.2  METHOD VALIDATION PARAMETERS 
Method validation and development processes cannot be separated, as the 
development chemist will not know whether the developed method parameters are 
acceptable until validation is complete. Results of validation may point out that a 
change in the method is necessary which may require redevelopment and 
revalidation.31 No Regulatory Agency will accept data which has been obtained by a 
non-validated method.32 
Following method development and optimization, a method is then subjected to a full 
validation as per the in-house protocol according to ICH guidelines. The following 
definitions of validation parameters are a combination of those outlined in the ICH 
guidelines, the FDA guides, and in-house standard work instructions specifically for 
method validation of dissolution methods.33, 34, 35, 36 
1.6.2.1 SPECIFICITY 
Specificity is defined as the ability of the assay method to measure specifically and 
accurately the analyte of interest in the presence of other compounds that might be 
expected to be present in the sample matrix. It is a measure of the absence of 
interference from components such as other actives, degradation products, impurities 
and excipients, thus ensuring that a measured response corresponds to a single 
component only.37  
This is performed using a Photo Diode-Array detector or in some cases a mass 
selective detector. 
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Figure 1.11: A Photo Diode Array Spectrum of a typical HPLC peak.38, 39 
Figure 1.11 (above) illustrates a typical HLPC peak with slices taken throughout the 
peak. Photodiode-array data was collected from each of these slices, and the apex 
spectrum collected across the peak. Shape differences in the photodiode-array 
spectra were calculated using software and their weighted averages are reported as 
purity angles. A threshold angle is a pseudo-detection limit for purity angles, is 
determined by multiple injections of the same sample. This threshold angle sets the 
limit above which the presence of an impurity is present. 
If the purity angle is less than the threshold angle then the peak is indicative of being 
spectrally pure, homogenous and a single entity.36 
Photo Diode-Array Analysis 
1. Determine the peak purity (by photo diode-array analysis) for the actives in the 
standard and sample solutions. 
2. Where samples have been stressed in order to obtain degradation, peak purity 
for the active compound(s) peak must be determined by photo diode-array 
analysis. 
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1.6.2.1.  SYSTEM PRECISION 
This parameter is a measure of the error contribution due to the chromatographic test 
equipment and electronics. A test is undertaken to determine the repeatability of 
results when repeating the assay, the result of which will show any inconsistencies in 
the equipment.  
Peak tailing must be less than 2.0. The column efficiency due to actives must be more 
than 3500 theoretical plates per 5 cm. The resolution between critical peaks (Peak 2 
/peak 3) should be greater than 4.0. The % RSD of the absorbance responses due to 
the respective actives for five replicate readings must be less than, or equal to 2.0 %.  
1.6.2.2 LINEARITY  
Linearity may be defined as the ability of the method to produce test results that are 
directly proportional to the analyte concentration within a given range. Proof of 
linearity justifies the use of single-point calibrations. It verifies that a sample solution is 
in a concentration range where analyte response is linearly proportional to 
concentration.35  
Requirement: 
Linearity is typically calculated by using an appropriate least-squares regression 
program. Typically, the correlation coefficient (R ≥ 0.99) demonstrates linearity. In 
addition, the y-intercept must not be significantly different from zero. 
1.6.2.3 ACCURACY 
Accuracy determines the level of agreement between the true value and observed 
value for test results. Constant or proportional systematic effects may cause a method 
to be inaccurate. The accuracy test determines whether such effects are present and 
whether these influence the results. The amount of analyte present in a test sample is 
not usually known; for this reason it is difficult to be certain how successful the 
method has been at extracting it from the matrix. One method of determining 
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accuracy is to add known but varying amounts of the analyte to the test sample, then 
extracting and measuring the analyte concentrations.40  
Requirement: 
The percentage recovery of active compound, for each solution prepared, must be 
within the 95.0 to 105.0 % limit of the actual amount.  
1.6.2.4 METHOD PRECISION (RUGGEDNESS) 
The precision of a test procedure expresses the closeness of agreement (degree of 
scatter) between a series of measurements obtained from multiple sampling of the 
same homogeneous sample under prescribed conditions.35 
1.6.2.4.1 REPEATABILITY 
Repeatability expresses the precision under the same conditions including the same 
analyst, same apparatus, identical reagents and short interval (this is the length of the 
validation period which is normally two weeks - if testing occurs outside of this period 
then the sample might have degraded resulting in incomparable results). 
The % RSD due to the respective active compound concentrations for six samples 
must not exceed 5.0 %. 
1.6.2.4.2 REPRODUCIBILITY 
Reproducibility of an analytical procedure expresses inter-laboratory variations of the 
repeatability test performed by a different laboratory, by a different analyst, on a 
different day using a different instrument (UPLC) and using different reagents. 
The % RSD due to the respective active compound concentrations for six samples 
must not exceed 5.0 %. 
The mean of six recoveries obtained for the dissolution method repeatability, and the 
mean of six recoveries obtained for the reproducibility measurements must not differ 
by more than 5.0 %. 
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1.6.2.5 RANGE 
The range of an analytical assay method is the interval between the upper and lower 
levels of active compound (including these levels) that will be demonstrated to be 
determined with precision, accuracy and linearity by the assay method. The ICH 
guidelines for the validation of an analytical procedure describes the range for 
dissolution testing to be ± 20 % over the specified range. The method range was 
determined as per an internal procedure based on the linearity and accuracy test 
concentrations.35  
1.6.2.6  STABILITY OF SOLUTION  
The standard / test (sample) solution is stored under conditions that guarantee 
stability. The stability of the standard is analyzed over a specified period of time, using 
a freshly prepared standard / test (sample) solution at each time interval for 
comparison. The test results must show that no loss of each active occurred, taking 
into account an allowed amount of assay variability of ±  2.0 % ( typically between 
98% and 102%) in the standard and test (sample) preparations while standing for the 
maximum time period specified in the method.35 
 If the solution is not stable under these conditions then the following aspects may 
need to be considered: 
• temperature (refrigeration may be needed) 
•  light protection (the use of amber glassware) 
•  and container material (plastic or glass) 
The procedure may state that the standards and samples need to be analyzed within 
a time period demonstrating acceptable standard and sample solution stability.41 
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1.6.2.7 MOBILE PHASE SHELF LIFE 
This aspect tests the stability of the mobile phase over time. This is done by 
comparing the adherence to the system suitability requirements of a mobile phase 
that was prepared and stored in typical mobile phase containers over a period of 7 
days to that of the initial solution.35 
1.6.2.8  ROBUSTNESS 
Robustness is a measure of an analytical procedure to remain unaffected by small but 
deliberate variations in procedural parameters listed in the method of analysis, which 
provides an indication of its suitability during normal usage. Robustness may be 
determined following the development of the analytical procedure. The system 
suitability is assessed according to the system suitability requirements, under each 
condition. If measurements are found to be susceptible to slight variations in 
operational conditions, a note must be made stating strict adherence to the specific 
parameters, including a precautionary statement.35  
1.7 PRODUCT INFORMATION  
For multi-active formulations, current pharmacopeia practice is to quantify each active 
individually.42 This means that for a tablet containing three actives, separate methods 
must be used to test each active before the approval and release of the product. This 
process is labour intensive, time consuming and expensive. 
During this investigation, the active components in the test product, to be labelled 
Product X, are paracetamol, caffeine and codeine phosphate. Paracetamol is one of 
the most popular analgesic and antipyretic drugs.43  Caffeine is a common stimulant,44 
while codeine phosphate has many medicinal properties which include analgesic, 
anti-tussive, anti-diarrheal and hypnotic properties.45 These three components form 
the basis of many pain medications. These three actives are also present in two other 
products (designated as Products Y and Z). 
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The physical and chemical properties of the three active components common to the 
three pharmaceutical formulations to be investigated, paracetamol, caffeine and 
codeine phosphate, are summarised in Table 1.2. Similar information is provided for 
the antihistamine components present in Products Y and Products Z in Table 1.3. 
One commonality in the structures of these active components is the conjugated 
systems. The alternating single and double bonds allow electrons to jump between 
orbitals that are extended pi-orbitals. This is known as conjugated chromophores. 
These chromophores are the parts of the molecules responsible for its colour. When 
the molecule absorbs a certain wavelength of light, colour appears. This property 
makes detection by means of UV possible.46 
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Table 1.2:  Description and physical properties of the components present in Products X, Y and Z
Active name Paracetamol  Caffeine Anhydrous Codeine phosphate hemihydrate 
Synonym Acetaminophen; 
N-Acetyl-p- aminophenol 
3,7-Dihydro-1,3,7-trimethyl-1,3,7-
trimethylxanthine 
7,8-didehydro-4,5-alpha-epoxy-3-methoxy-17-methyl-
morphinan-6-alpha-ol phosphate (1:1) 
Structure  
 
 
 
Molecular formula C8H9NO2 C8H10N4O2  C18H21NO3·H3PO4·½H2O 
CAS No. 103 - 90 – 2 58-08-2 41444-62-6 
Melting Point 169.0 ºC -170.0 ºC 227.0°C -228.0°C - 
Form White crystals or crystalline powder Odourless white needles or powder.  White crystalline powder.  
Solubility Very slightly soluble in cold water, 
significantly more soluble in hot, water; 
soluble in ethanol, methanol, acetone 
and ethyl acetate; very slightly soluble 
in ether; virtually insoluble in petroleum 
ether, pentane and benzene. 
2.17 g/100 mL (25 °C); 18.0 g/100 
mL (80 °C); 67.0 g/100 mL (100 °C) 
Very slightly soluble in cold water, 
considerably more soluble in hot, 
water; soluble in ethyl acetate; 
slightly soluble in  petroleum ether. 
Soluble in water (1 in 4), practically insoluble in 
Chloroform and ether. 
H 3 P O 4 1 /2  H 2 O,,
O
H
H
H
H N
H 3 C O O H
C H 3
CONFIDENTIAL INTELLECTUAL PROPERTY OF ASPEN PHARMACARE Page 35 
 
 
 
Table 1.2:  Description and physical properties of the components present in Products X, Y and Z. continued 
  
 
 
 
Table 1.3: Description and physical properties of the antihistamine components  
 
 
 
 
 
 
  
Active name Paracetamol  Caffeine Anhydrous Codeine phosphate hemihydrates 
Dissociation 
constant  
pKa 9.5 (25 °C)  -0.13 – 1 .22 (25°C)  pKa 8.2 (20 °C) 47,48 
Ultra Violet 
Spectrum  
Aqueous acid 245nm and  
aqueous alkaline 257 nm  
Aqueous acid 273 nm, No 
alkaline shift  
Aqueous acid 285 nm, No alkaline shift 
pH 5.5 – 6.5 6.9 (1 % aqueous solution) data not available 
Use Paracetamol is one of the 
most popular analgesic and 
antipyretic drugs.34 
Caffeine is a xanthine alkaloid 
that is a psychoactive stimulant 
drug.49 Caffeine occurs as 
odourless white needles or 
powder.50,51 
Codeine is an alkaloid found in the opium poppy. It has many 
medicinal properties which include analgesic, anti-tussive, 
anti-diarrheal and hypnotic properties. 
Active name Diphenhydramine HCl Doxylamine Succinate 
Synonym Benzhydramine Hydrochloride; Dimedrolum; 
2-(diphenylmethoxy)-N.N-dimethyl,-hydrochloride 
2-[α-[2-(dimethylamino)ethoxy]-α-methylbenzyl]pyridine 
succinate (1:1) 
Structure 
 
 
Molecular formula C17H21NO, HCl C17H22N2O·C4H6O4 
CAS No 147-24-0 562-10-7 
Melting Point 166.0-170.0 °C 100.0 – 140.0 °C 
. HC lO N
C H 3
C H3
O
O
H O
O H
O
N
N
H 3 C
H 3 C
C H 3
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Table 1.3: Description and physical properties of the antihistamine components continued. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Form White crystalline powder which slowly darkens on 
exposure to light.  
White or creamy-white powder 
Solubility Very soluble in water, freely soluble in alcohol;,very 
slightly soluble in  benzene and in ether. 
 
2.17 g/100 mL (25 °C); 18.0 g/100 mL (80 °C); 67.0 g/100 mL (100 
°C) Very slightly soluble in cold water, considerab ly more soluble in 
hot, water; soluble in ethyl acetate; slightly soluble in  petroleum 
ether. 
Dissociation constant   pKa 9.0 (25 °C)  4.4, 9.2 (25 °C) 
Partition coefficient Log p (octanol / water) 3.3 Log p (octanol / water), 2.4 
Ultra Violet Spectrum  Aqueous acid 252 and 257 nm, No Alkaline shift  Aqueous acid 261 nm, No Alkaline shift  
pH 4 – 6 for a 5 %w/v 6.9 (1 % aqueous solution) 
Use Diphenhydramine is an ethanolamine derivative, 
antihistamine, with antimuscarinic and pronounced 
sedative properties it form part of many proprietary 
preparations.52 
Doxylamine is an ethanolamine derivative, sedating antihistamine; 
with antimuscarinic and pronounced sedation effect it is used as a 
hypnotic in short terms treatment of insomnia and for the treatment 
of coughs and the common cold in compound preparation.”53 
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There have been a number of reports dealing with various analytical techniques for 
the determination of paracetamol and its combinations, such as UV spectroscopy, 
thin layer chromatography, gas chromatography-mass spectrometry and high 
performance liquid chromatography (HPLC). Conventional literature, compendial 
monographs in the USP and BP provide methodologies for the analysis of binary 
combinations such as paracetamol-codeine phosphate.54  
 
Aspen products are multi-active consisting of three or more combinations and are 
hence unique. According to current pharmacopeial practice, each individual active 
component in a multi-active product requires separate assay using a specifically 
validated assay method for each active.  
 
Several HPLC methods for the simultaneous determination of the ternary mixture of 
paracetamol, caffeine and codeine phosphate have been reported in literature. 
Kartal55, for example, describes a method using a µ-Bondapak C8 column. This type 
of column technology is regarded as out of date1 since the relatively large column 
particles (10 µm) and their spherical nature result in broad peaks. Schmidt56 
describes a method for the determination of these actives collected on swabs from 
pharmaceutical manufacturing equipment. The column used is a Synergy Hydro 
RP18 150 mm by 3 mm with a particle size of 4 µm. Yu-Pen et.al57 describes an 
isocratic method using an Intersil ODS 5 µm, 250 mm by 4.6 mm column for the 
determination of various components in a cold medicine complex. This included 
paracetamol and caffeine. The technique of UPLC is therefore ideal to separate and 
analyse these products with major time and cost benefits.   
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CHAPTER 2: EXPERIMENTAL 
2.1 INTRODUCTION 
A UPLC chromatographic method was developed and evaluated for the analysis of 
the three active substances contained in formulation compositions targeted to relieve 
symptoms associated with the common cold. The column used contained a new High 
Strength Silica (HSS) UPLC stationary phase. This stationary phase was selected 
due to its ability to enhance the retention of polar analytes while also having good 
chromatographic selectivity for hydrophobic species.58  
The actives in the tablet formulation for Product X are present in the following 
percentages: paracetamol 50 % (m/m), caffeine 5 % (m/m) and codeine phosphate   
2 % (m/m). The initial instrumental method and analytical parameters for the method 
development were based on a reported method by W. Jobert,59 and the current in-
house HPLC methods for the analyses of these active substances. 
2.2 METHODOLOGY FOR METHOD DEVELOPMENT FOR PRODUCT X 
 
2.2.1 REAGENTS 
The reagents and standards used for UPLC analysis, together with their sources and 
respective grades, are listed in Table 1 and 2 and were used as received.    
Table 2.1: Reagents for UPLC analysis 
Chemical Name Chemical Formula Source Grade 
Water Milli Q Millpore n/a 
Acetonitrile CH3CN Merck HPLC / UHPLC 
Trifluoroacetic acid 
(TFA) 
C2HF3O2 Sigma-Aldrich HPLC 
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Table 2.2: Standards used in the analysis 
Chemical Name Chemical Formula Source 
Paracetamol C8H9NO2 Fine Chemicals, REFERENCE 
STANDARD 
Caffeine C8H10N4O2 Shandong Xinhua Pharmaceuticals, 
China, REFERENCE STANDARD 
Codeine phosphate C18H21NO3·H3PO4·½H2O Fine Chemicals, REFERENCE 
STANDARD 
Diphenhydramine HCl C17H21NO, HCl Fine Chemicals, REFERENCE 
STANDARD 
Doxylamaine Succinate C17H22N2O·C4H6O4 Fine Chemicals, REFERENCE 
STANDARD 
 
The dissolution medium used during dissolution studies for Products X and Z was 0.1 
M hydrochloric acid (HCl), while water was used as dissolution medium for Product Y. 
2.2.2 CHROMATOGRAPHIC SYSTEM 
The UPLC system consisted of a Waters Acquity UPLC system and Acquity UPLC 
PDA detector, a computer for data processing which was equipped with the 
chromatographic data software Empower Version 2.0. Method development was 
carried out on the ACQUITY UPLC HSS T3, 1.8 µm, 50 x 2.1 mm column. 
2.2.3 PREPARATION OF STANDARD SOLUTIONS 
2.2.3.1  Preparation of Assay Standard – Product X: 
Approximately 32 mg of paracetamol, 64 mg of caffeine and 16 mg of codeine 
phosphate reference standards (masses accurately weighed) were transferred into a 
100 mL volumetric flask.  A volume of 50 mL of methanol was added to the volumetric 
flask and sonicated for 5 minutes. The solution was then made up to volume with 
solvent and mixed well. 
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2.2.3.2  Preparation of Dissolution Standard – Product X: 
Approximately 90 mg of codeine phosphate reference standard was accurately 
weighed and transferred into a 50 mL volumetric flask. A volume of 5 mL of 
acetonitrile was added and the solution sonicated for 10 minutes. The solution was 
then made up to volume with solvent and mixed well (codeine stock solution). 
Approximately 711 mg of paracetamol reference standard and 71 mg of caffeine 
reference standard was accurately weighed into a 200 mL volumetric flask, to which 
10 mL of codeine stock solution was added by pipette. A volume of 5 mL of 
acetonitrile and 50 mL of solvent was added. The solution was then sonicated for 10 
minutes, cooled and made up to volume with solvent. 
2.2.3.3  Preparation of 1 mg/mL antihistamine standard – Products Y and 
Z: 
Approximately 10 mg each of diphenhydramine HCl and doxylamine succinate 
reference standard was weighed and transferred into two separate 100 mL volumetric 
flasks. A volume of 5 mL of acetonitrile was added and the solutions sonicated for 10 
minutes each. The solutions were then made up to volume with dissolution media and 
mixed well. The resulting solutions were then filtered through a 0.22 µm membrane 
filter having discarded the first few milliliter of filtrate and placed into a vial. 
2.2.4 PREPARATIONS OF SAMPLE SOLUTIONS 
2.2.4.1 Preparation of Assay samples: 
Approximately 643 mg of the powdered sample X was weighed into a 500 mL 
volumetric flask, and 50 mL of solvent was added. The solution was sonicated for 5 
minutes. The solution was then made up to volume with solvent and mixed well 
(solution 1). A portion of the solution was then filtered through a 0.22 µm membrane 
filter, discarding the first few milliliter of filtrate. An aliquot of this filtered sample was 
placed into an HPLC vial for the determination of caffeine and codeine phosphate. A 
5 mL aliquot of solution 1 was pipetted into a 100 mL volumetric flask. The solution 
was then made up to volume with solvent and mixed well. The resulting solution was 
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then filtered through a 0.22 µm membrane filter having discarded the first few milliliter 
of filtrate and placed into an HPLC vial for the determination of paracetamol (solution 
2). 
2.2.4.2  Preparation of Dissolution Sample: 
A volume of 900 mL of dissolution medium was added to each of the 6 vessels of the 
dissolution apparatus sited in the water bath. The temperature of the medium was 
allowed to equilibrate to 37 ºC. The baskets were set to rotate at 100 rpm. One tablet 
was transferred to each of the six baskets and at time “0” minutes the baskets were 
immersed in the dissolution medium. After exactly 30 minutes, 4 mL aliquot from each 
vessel was removed and filtered through a 0.22 µm filter into separate vials. 
2.2.5  CHROMATOGRAPHIC CONDITIONS 
The reported method of W. Joubert from Microsep used the following UPLC 
conditions:52  
Mobile phase:     
  
line A1: Acetonitrile (10 %) 
line B1: 0.15 % Trifluroacetic acid (TFA) in water (90 
%) 
Weak needle wash Acetonitrile: Water (10: 90); (600 µl) 
Strong needle wash Acetonitrile (200 µl) 
Flow 0.9 mL / min  
Injection volume and injection mode 5 µl; Partial Loop with needle overfill 
        
Loop Size: 10 µl  
 
Column Temperature 40 ºC 
Detection UV @ 220 nm 
Solvents  Acetonitrile/ Water (50:50); Water 
Sampling rate  20Hz 
Time constant 0.05 
UV Block  On 
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Line B mobile phase was prepared by pipetting 1.5 mL of trifluoroacetic acid (TFA) 
into 1000 mL of water contained in a 1000 mL mobile phase bottle. Both mobile 
phases were filtered through 0.22 µm filters before use. 
2.2.6  CHROMATOGRAPHIC CONDITIONS FOR VALIDATION 
The chromatographic conditions are defined by the optimized method developed for 
product X (refer to section 3.1;Table 3.3). 
 
2.3 METHODOLOGY FOR METHOD VALIDATION FOR PRODUCT X  
 
2.3.1 SPECIFICITY 
A series of samples were prepared as detailed below (Table 2.3) and the samples 
were injected into the UPLC system using the UPLC conditions described in Section 
2.2.5. The detector was set to scan across the UV range between 210 and 300 nm. 
Peak purity (by photo diode-array analysis) for the actives in the standard and sample 
solutions was evaluated by comparing the magnitude of the purity angle to the 
threshold angle 
Table 2.3: Sample preparation for specificity samples 
Solution 
number 
Preparation 
1 Solvent: 0.1M HCl  
2 Placebo: 14.7 mg placebo dissolved in 100 mL of 0.1M HCL.  
3 Actives at working concentration: The standard solution was prepared as per §2.2.3.2 
4 Product at working concentration: The product was prepared as per §2.2.4.2, that is one tablet 
dissolved in 900 mL with dissolution media (0.1 M HCL). 
5 Paracetamol at the working concentration: 177.8 mg of paracetamol reference standard was 
weighed into a 50 mL volumetric flask. The paracetamol was dissolved with the aid of 
sonication by adding 25 mL of solvent and 5 mL acetonitrile into the above volumetric flask 
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and diluting to volume with solvent. 10 mL of this solution was diluted to 100 mL with 0.1 M 
HCl 
6 Caffeine at the working concentration: 71 mg of caffeine reference standard was weighed into 
a 200 mL volumetric flask. The caffeine was dissolved with the aid of sonication by adding 25 
mL of solvent and 5 mL acetonitrile into the above volumetric flask and diluting to volume with 
0.1 M HCl. Form the resulting solution 10 mL was diluted to 100 mL with 0.1 M HCl.  
7 Codeine phosphate at the working concentration: 90 mg of codeine phosphate reference 
standard was weighed into a 50 mL volumetric flask. The codeine phosphate was dissolved 
with the aid of sonication by adding 5 mL of acetonitrile into the above volumetric flask and 
diluting to volume with 0.1 M HCl. 10mL of this solution was diluted to 200 mL with solvent. 
This solution was further diluted by pipetting 10 mL of the resulting solution to 100 mL with 0.1 
M HCl.  
8 Combination of actives and known degradation products:  
Codeine stock solution: 90 mg of codeine phosphate reference standard was weighed into a 
50 mL volumetric flask. The codeine phosphate was dissolved with the aid of sonication by 
adding 5 mL of acetonitrile into the above volumetric flask,  
Assay Stock solution: 711 mg of paracetamol reference standard and 71 mg of caffeine 
reference standard was weighed into a 200 mL volumetric flask. 10 mL of the codeine stock 
solution was then added into the above volumetric flask. The actives were dissolved by adding 
50 mL of 0.1 M HCl and sonicating. (Assay stock solution) 
Degradation stock solution 1: 2.25 mg codeine-n-oxide and 1.5 mg of codenone was weighed 
into a 50 mL volumetric flask (labeled stock solution 1), dissolved and diluted to volume with 
0.1 M HCl.  
Degradation stock solution 2: 50 mg of 4-aminophenol was weighed into a 50 mL volumetric 
flask. Make to volume with 0.1 M HCl. 5 mL of the above solution was diluted to 50 mL with 
solvent (labeled stock solution 2).  
Lastly 10 mL of the assay stock solution and 10 mL of both degradation stock solution 1 and 
degradation stock solution 2 was pipetted into a 100 mL volumetric flask and diluted to volume 
with 0.1M HCl. 
9 Stability sample, drug product stressed for 24 months at working concentration: The 
“stressed” drug product was prepared by dissolving one stressed tablet in 900 mL with 
dissolution media. This sample was exposed to 40ºC / 75% relative humidity for a period of 24 
months  
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The requirements for specificity are that the solvent solution (solution 1) and placebo 
solution (solution 2) must not contain any components which co-elute with the active 
compound peaks (solution 3). Any degradation products formed must be well 
resolved (at least baseline resolution ≥ 1.5) from the active compound peaks and 
must elute within the specified run time. The photo diode-array results must show that 
the active peaks in the standard, sample and stressed sample solutions are indicative 
of being pure. 
2.3.2 SYSTEM PRECISION 
Five replicate standard injections were performed and the system suitability 
calculated using the empower software. The requirements for system suitability are 
that the percentage relative standard deviation (% RSD) for the peak responses due 
to the actives are less than or equal to 2.0 %. The peak tailing factor must be less 
than 2.0 and the column efficiency due to the respective actives must be more than 
3500 theoretical plates per 5 cm. The resolution between caffeine and codeine 
phosphate should be greater than 4.0.  
2.3.3 LINEARITY  
A calibration curve was prepared and the linearity demonstrated over the active 
compounds concentration range of 0 to 120 % relative to the working solution 
concentration. Each of the solutions was assayed in duplicate. A simple linear 
regression curve of sample responses, y, versus active compound concentrations, x, 
is constructed using Excel.60 The requirements for linearity are that the correlation 
coefficient of the regression line must be greater than or equal to 0.99.  
2.3.3.1  Preparation of stock solutions 
Ninety (90) mg of codeine phosphate reference standard was weighed into a 50 mL 
volumetric flask. The codeine phosphate was dissolved by adding 5mL of acetonitrile 
and sonicating for a period of 5 minutes. The solution was allowed to cool and was 
made up to volume with 0.1 M HCl. 711 mg of paracetamol reference standard and 
71 mg of caffeine reference standard was weighed into a 200 mL volumetric flask. An 
CONFIDENTIAL INTELLECTUAL PROPERTY OF ASPEN PHARMACARE Page 45 
 
aliquot of ten (10) mL of the codeine solution was then pipetted into the volumetric 
flask containing the paracetamol and caffeine. This solution was dissolved by adding 
5 mL of acetonitrile and sonicating for 10 minutes. The solution was allowed to cool 
and made to volume using 0.1M HCl. This solution was then used to prepare the 
linearity samples as illustrated in Table 2.4. 
Table 2.4: Preparation of Linearity Sample Solutions 
% Preparation 
Theoretical 
Concentration 
(mg / mL) 
Paracetamol 
Theoretical 
Concentration 
(mg / mL) 
Caffeine 
Theoretical 
Concentration  
(mg / mL) 
Codeine 
Phosphate 
0 Solvent 0 0 0 
10 1 mL stock soln →100 mL 0.0355 0.00355 0.0009 
20 2 mL stock soln →100 mL 0.0711 0.00710 0.0018 
30 3 mL stock soln → 100 mL 0.1067 0.01067 0.0027 
40 4 mL stock soln → 100 mL 0.1422 0.0142 0.0036 
50 5 mL stock soln → 100 mL 0.1778 0.01775 0.0045 
60 6 mL stock soln → 100 mL 0.2133 0.0213 0.0054 
70 7 mL stock soln → 100 mL 0.2489 0.02485 0.0063 
80 8 mL stock soln →100 mL 0.2844 0.0284 0.0072 
90 9 mL stock soln → 100 mL 0.3195 0.03195 0.0081 
100 10 mL stock soln → 100 mL 0.3555 0.0355 0.009 
110 11 mL stock soln → 100 mL 0.3911 0.03905 0.0099 
120 6 mL stock soln → 50 mL 0.4266 0.0426 0.0108 
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2.3.4 ACCURACY 
Accuracy samples were prepared by adding all the placebo ingredients equivalent to 
one tablet (134 mg) into each of the six dissolution vessels containing 0.1 M HCl 
dissolution medium. The dissolution medium was equilibrated to 37 ºC. Each of the 
vessels was spiked with 10, 20, 50, 80, 100 and 120 % of active compound. The 
dissolution was run as specified in section 2.2.4.2 and after 30 minutes, samples 
were drawn and assayed in duplicate. The stock solution for caffeine and codeine 
phosphate was used for the spiking of the accuracy samples. 
 
2.3.4.1 Preparation of spiking solutions 
Approximately 128 mg of caffeine reference standard and 32 mg of codeine 
phosphate was weighed into a 200 mL volumetric flask. The solution was dissolved 
by the addition of 10 mL of acetonitrile and sonicated for a period of 10 minutes. The 
solution was allowed to cool down and made up to volume with 0.1M HCl. The 
resulting solution was labeled as stock solution 1 and was used to spike the 
dissolution vessel to produce concentration levels of 10, 20, 50, 80 and 100 %. The 
spiking of the 120 % concentration, approximately 160 mg of caffeine reference 
standard and 40 mg of codeine phosphate was weighed into a 50 mL volumetric 
flask. The solution was dissolved by the addition of 10 mL of acetonitrile and 
sonicated for a period of 10 minutes. The solution was allowed to cool down and 
made up to volume with 0.1M HCl. The resulting solution was labeled as stock 
solution 2. Table 2.5 below summarises the preparation of the accuracy samples at 
the various % concentrations.  
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Table 2.5: Summary of Accuracy sample preparation at various % concentrations 
 
The requirements for accuracy are that the percentage recovery of active 
compounds, for each solution prepared, must be within the 95.0 to 105.0 % limit of 
the actual amount.  
2.3.5 METHOD PRECISON (RUGGEDNESS)  
2.3.5.1 REPEATABILITY: 
Samples were prepared by adding one tablet into each of the six dissolution vessels 
containing 0.1 M HCl, dissolution medium, which was equilibrated at 37 ºC. The 
dissolution was allowed to run for a period of 30 minutes. Samples were drawn at the 
end of the dissolution period and analyzed using the UPLC. The requirements for 
repeatability are that the relative standard deviations for the six determinations must 
not exceed 5.0 % 
 
 
Vessel No. 
[% Concentration] 
Accuracy Sample Preparation 
Vessel No 1: [10 %] 5 mL stock solution 1 + 133 mg placebo + 32 mg of paracetamol → 900 mL 
Vessel No 2: [ 20 %] 10 mL stock solution  1 + 133 mg placebo+ 64 mg of paracetamol → 900 mL 
Vessel No 3: [50 %] 25 mL stock solution 1 + 133 mg placebo+ 160 mg of paracetamol → 900 mL 
Vessel No 4: [80 %] 40 mL stock solution 1+ 133 mg placebo + 256 mg of paracetamol → 900 mL 
Vessel No 5: [100 %] 50 mL stock solution 1+ 133 mg placebo+ 320 mg of paracetamol → 900 mL 
Vessel No 6: [120 %] 12 mL stock solution 2 + 133 mg placebo+ 384 mg of paracetamol → 900 mL 
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2.3.5.2 REPRODUCIBILITY: 
Samples were prepared as described in section 2.3.5.1 by a different laboratory, by a 
second analyst on a different day using a different instrument (UPLC) and using 
different reagents. The requirements for reproducibility are that the relative standard 
deviations for the six determinations are not more than 5.0 %. The % difference in the 
mean results obtained for the six determinations for the repeatability and the 
reproducibility measurements must not differ by more than 5.0 %. 
2.3.6 RANGE 
Based on the results obtained from the linearity and accuracy tests, the range for the 
method is defined. 
2.3.7 STABILITY OF SOLUTION  
Solutions of the standard and sample were prepared which contained the actives at 
the working concentration. (Refer to sections 2.2.3.2 and 2.2.4.2 for the preparation of 
the standard and sample solutions for dissolution.) A portion of these solutions were 
then kept at room temperature (25 ºC) and under refrigerated condition (5 ºC). The 
standard and sample solutions were analyzed over a specified period using the 
original sample solution response for comparison. Solutions of the standard and 
sample were analysed at the following times: 0, 8, 24 and 48 hours. 
All these standard and sample solutions were assayed by duplicate injections on the 
UPLC, using the time zero standard for system suitability.  
The requirement for stability of solution are that the assay results must show that no 
loss of active occurred, (taking into account an allowed amount of assay variability 
(i.e. ±  5.0 %) in the standard and sample solutions while standing for the maximum 
time period specified in the method. No degradation product peaks should be 
observed. All unknown peaks must be monitored at each time point and compared to 
the area responses of the same unknown peaks in the time zero (T0) standard and 
CONFIDENTIAL INTELLECTUAL PROPERTY OF ASPEN PHARMACARE Page 49 
 
time zero (T0) sample chromatograms. The areas of these unknown peaks must not 
increase notably.  
2.3.8 MOBILE PHASE SHELF LIFE 
Mobile phase was prepared and stored in a typical mobile phase container over a 
period of 7 days. The mobile phase appearance was noted. The solution must be 
clear and show no signs of precipitation or cloudiness after 7 days. The system 
suitability test was determined as described in section 2.3.2 after 7 days. These 
results were compared to the system suitability of the initial “fresh” solution. The 
requirements were the same as for the system suitability test (§2.3.2) for this method.  
2.3.9 ROBUSTNESS 
To test robustness, small but deliberate changes to the method of analysis were 
performed to show that the method is robust. The following changes were performed: 
1. change in column batch numbers (This was performed during method 
precision). 
2. change in the mobile phase ratios: acetonitrile: TFA from15:85 to 5:95) 
3. change in column temperature by ± 5 ºC 
4. change in flow rate by ± 0.1 mL / min. 
A standard solution was prepared and injected five times and the system suitability 
assessed according to the system suitability requirements under each listed 
condition.  
The requirements for robustness were that if measurements were found to be 
susceptible to slight variations in operational conditions, a note must be made in the 
final method stating strict adherence to the specific parameters, including a 
precautionary statement.  
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2.4 METHODOLOGY FOR THE APPLICATION OF THE DEVELOPED 
UPLC METHOD FOR THE ANALYSIS OF PRODUCTS Y  
The Validated method used for Product X was used unchanged for the analysis of 
products Y and Z. 
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CHAPTER 
In this section the results obtained for 
UPLC method for the simultaneous analysis of all three active substances contained 
in Product X, as well as the results obtained for the use of this method for
of the active components contained in two similar produ
discussed. 
3.1 METHOD DEVELOPMENT F
The instrumental conditions recommended by Waters (section 2.2.5) were
starting point for the UPLC method development. 
for the analysis of the assay standard under these conditions 
water (50:50) as the solvent
Figure 3.1:  Initial chromatogram for the assay standard
The above chromatogram shows that adequate separation between the three acti
substances (Rsparacetamol/caffeine
for all components) was obtained in a total run time of only 1.2 minutes. These 
conditions do, however, result in a somewhat noisy baseline which results
“impure peak” analysis result by the photo
under these conditions, the system backpressure was approximately 11796
maximum system backpressure that the instrument will allow before it cuts out is
 
3: RESULTS AND DISCUSSI
the development and method validation 
cts, Products Y and Z
OR PRODUCT X 
The UPLC chromatogram obtained 
when
 is shown in Figure 3.1. 
 
 
= 10.5; Rscaffeine/codeine phosphate = 5.5; k’
-diode array (PDA) detector. In addition, 
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15 000 psi. So as not to exceed this backpressure, it is recommended that 
separations be developed with backpressures around 10 000 
common practice to develop methods on new columns
backpressure associated with the 
pressure on the new column,
Using the reduced flow rate of 0.65 
conditions (as mentioned in section 2.2.5) 
Figure 3.2 for the analysis of the assay 
Figure 3.2:  Chromatogram at a reduced flow rate
The reduction in flow rate to 0.65 
1.2 minutes to 1.6 minutes (Figure 3.2). 
Gaussian behaviour (Tf
fronting is normally due to column overload, e.g. through injecting 
concentrated sample onto the column. This may be overcome b
injection volume or diluting the sample solution. The injection volume was 
subsequently reduced to 2 µl. Under these conditions
flow rate of 0.65 mL / min and  injection volume of 2
impure peak for paracetamol only (see for example
 
. As 
column increases. Therefore,
 the flow rate was reduced to 0.65 mL
mL/min and otherwise similar instrumental 
resulted in the chromatogram shown in 
standard. 
 
mL/min results in the extension of the run time
The peak shape does not strictly show 
 = 0.9), an indication of some degree of peak fronting. Peak 
 (section
 µl) as  the PDA data indicate a
 Table 3.1). 
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 2.2.5 at a reduced 
n 
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Table 3.1: The PDA results obtained for the assay standard  
Compound Purity Angle Purity Threshold Purity flag 
(Yes / No) 
Paracetamol 11.873 5.068 Yes 
Caffeine 0.138 0.286 No 
Codeine phosphate 0.638 0.771 No 
 
The peak shapes obtained were somewhat a-symmetrical, flat-topped peaks. To 
obtain better peak shapes, the number of data points recorded across the peak was 
increased from 20 Hz to 40 Hz on the detector. This resulted in a slight improvement 
in peak shape. To further improve the peak shapes a change in solvent from an 
acetonitrile: water mixture (50:50) to the dissolution media (0.1 M HCl) was 
investigated.  
Injection of the dissolution sample prepared in dissolution media 0.1 M HCl results in 
a smoother baseline; hence the solvent effect experienced when injecting the 
standard prepared in with acetonitrile:water (50:50) was reduced.  
Current HPLC methods for the analysis of the three active substances in Product X 
use analytical wavelengths (λ max) of 280 nm for paracetamol and caffeine, but 220 
nm for codeine phosphate. The UV spectra generated with the PDA detector (Figure 
3.3) analysing at the same conditions as section 2.25 with the above mentioned 
changes show absorption maxima at 246 nm for paracetamol, 271 nm for caffeine 
and 283 nm for codeine phosphate. All three actives, however, also exhibit a strong 
absorbance at 220 nm, which is the recommended wavelength used for the preceding 
analyses.53 
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Figure 3.3:  PDA Spectral data 
Once a satisfactory separation was obtained, the
in Table 3.2 were used to perform a system precision analysis.
Table 3.2: Final UPLC instrumental conditions
Mobile phase:  
  
Weak needle wash 
Strong needle wash 
Flow 
Injection volume an mode 
Loop Size: 
Column Temperature 
Detection 
Solvents  
Sampling rate  
Time constant 
UV Block  
 
System precision analysis 
dissolution standard solut
 
for paracetamol, caffeine and codeine phosphate
 final UPLC parameters as tabulated 
 
 
line A1: Acetonitrile (10 %)
line B1: 0.15 % TFA in water (90 %)
Acetonitrile: Water (10: 90); (600 
Acetonitrile (200 µl) 
0.65 mL / min  
2 µl ;Partial Loop with needle overfill
10 µl  
40 ºC 
UV @ 220 nm 
0.1 M HCl 
40Hz 
0.05 
On 
was performed by injecting five replicate injections
ion. The percentage relative standard deviation (% RSD) for 
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each active substance, the tailing factor, and efficiency (theoretical plate count) were 
determined. 
Table 3.3:  System precision data obtained for a series of standard injections 
Injection 
number 
Peak area 
 Paracetamol Caffeine Codeine 
1 2062045 256264 54702 
2 2064405 256715 53788 
3 2063126 256901 55547 
4 2069234 257890 56249 
5 2063184 259206 54939 
    
Mean 2064399 257395 55045 
SD 2829.105 1173.706 923.384 
% RSD 0.1 0.5 1.7 
Peak 
Tailing 
1.5 1.3 1.2 
Platecount 3251 4207 3727 
 
For five replicate injections the % RSD was 0.1% for paracetamol, 0.5 % for caffeine 
and 1.7 % for codeine phosphate. The retention factor k’1 was calculated, by the 
software, to be 1.5, Tf = 1.3 for all components, and the theoretical plate count per 5 
cm was found to be approximately 4420. Figure 3.4 illustrates an example of a 
chromatogram of a sample obtained during dissolution testing using the final 
instrumental conditions (as shown in Table 3.3) for the UPLC analysis method for the 
simultaneous analysis of the three active substances in Product X . 
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Figure 3.4:  Sample chromatogram 
3.3 
3.2 METHOD VALIDATION FO
3.2.1 SPECIFICITY 
The chromatograms obtaine
shown in appendix 1. Each chromatogram was examined for compounds that may 
interfere or co-elute with the paracetamol, caffeine and codeine phosphate peaks. 
The chromatographic results are summari
peak purity results in Table 3.
Table 3.4:  Summary of chromatographic results
Solution 
number 
1 Solvent:No peaks due to solvent were detected.
2 Placebo: No peaks due to placebo were detected.
3 
Drug active at working concentration (standard
Peaks due to paracetamol, caffeine and codeine phosphate 
eluted at 0.51, 0.95 and 1.38 minutes respectively.
4 
Drug product at working concentration:
Peaks due to paracetamol, caffeine and codeine phosphate 
eluted at 0.51, 0.95 and 1.39 minutes respectively.
 
– final UPLC conditions as mentioned in Table 
R PRODUCT X 
d for the series of specificity samples (section 2.3.1) are 
zed in Table 3.4, and the photo
5. 
– Method specificity
Results and observations 
 
 
 solution): 
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-diode array 
 
Reference 
Figure 1, appendix 1 
Figure 2, appendix 1 
Figure 3, appendix 1 
Figure 4, appendix 1 
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5 
Paracetamol at the working concentration: 
A peak due to paracetamol eluted at 0.52 minutes. Figure 5, appendix 1 
6 
Caffeine at the working concentration: 
A peak due to caffeine eluted at 0.98 minutes. Figure 6, appendix 1 
7 
Codeine phosphate at the working concentration: 
A peak due to codeine phosphate eluted at.1.44 minutes. Figure 7, appendix 1 
8 
Combination of actives and known degradation products: 
Peaks due to 4-aminophenol (0.26), an unknown (0.30), 
paracetamol (0.51), caffeine (0.96), codeine-n-oxide (1.26), 
codeine phosphate (1.43) and codenone (2.91) (times in 
parentheses are in minutes). 
Figure 8, appendix 1 
9 
Stability sample, drug product stressed for 24 months at 
working concentration: 
Peaks due to 4-aminophenol (0.26), an unknown (0.30), 
paracetamol (0.51), caffeine (0.96), and codeine phosphate 
(1.43) (times in minutes) 
Figure 9, appendix 1 
 
Table 3.5: PDA-peak purity results  
Solution 
number 
Sample name 
Purity angle 
(PA) 
Threshold 
angle (TA) 
Impurity 
flagged 
Reference 
3 
Drug active at working 
concentration: (standard 
solution) paracetamol 
2.522 3.340 No 
Figure 10, 
appendix 1 
3 
Drug active at working 
concentration: (standard 
solution) caffeine 
0.060 0.259 No 
Figure 11, 
appendix 1 
3 
Drug active at working 
concentration: (standard 
solution) codeine 
phosphate 
1.110 1.900 No 
Figure 11, 
appendix 1 
4 
Drug product at working 
concentration: 
2.254 3.115 No 
Figure 12, 
appendix 1 
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paracetamol 
4 
Drug product at working 
concentration: 
 Caffeine 
0.060 0.258 No 
Figure 12, 
appendix 1 
4 
Drug product at working 
concentration: 
   codeine phosphate 
1.291 1.827 No 
Figure 13, 
appendix 1 
9 
Stability sample - 
paracetamol 
2.947 3.505 No 
Figure 14, 
appendix 1 
9 
Stability sample -  
caffeine 
0.064 0.257 No 
Figure 14, 
appendix 1 
9 
Stability sample -  
codeine phosphate 
1.673 1.968 No 
Figure 15, 
appendix 1 
 
The results shown in Appendix 1 and summarized in Tables 3.3 and 3.4 do not 
indicate any problem areas: no co-eluting components; unambiguous identification of 
paracetamol, caffeine and codeine phosphate peaks; baseline separation of all peaks 
(Rs > 1.5). No additional unknown or known degradation products were observed for 
the stability sample (solution 9). The photo diode-array results in Table 3.4 show that 
the active peaks in the standard, sample and stability sample solutions were 
spectrally homogenous. The method can therefore be considered specific for the 
quantification of paracetamol, caffeine and codeine phosphate in the formulation for 
Product X.  
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3.2.2 SYSTEM PRECISION  
System precision was performed the results of which are tabulated in Table 3.6 
Table 3.6:  System precision data obtained for Product X 
Injection 
number 
Peak area 
 Paracetamol Caffeine Codeine 
1 2108477 258335 55975 
2 2079854 253909 54750 
3 2077873 254208 54185 
4 2074174 254486 54441 
5 2066153 253158 53729 
 
Mean 2081306 254819 54616 
SD 16067.3 2026.9 846.8 
% RSD 0.8 0.8 1.6 
Peak Tailing 1.3 1.2 1.1 
Platecount 3615 4853 4791 
 
The results summarized in Table 3.5 indicate that the performance of the analytical 
system was within specification. The peak tailing was found to be 1.3, 1.2 and 1.0 for 
paracetamol, caffeine and codeine phosphate, respectively, which meet the 
requirement of not more than 2.0. The column efficiency due to the respective actives 
was found to be above 3000 theoretical plates per 5 cm. The average resolution 
between caffeine and codeine was 5.8, above the limit of 4.0. The % RSD of the 
absorbance responses due to actives for five replicate was found to be 0.8%, 0.8% 
and 1.6% for paracetamol, caffeine and codeine phosphate, respectively, which meet 
the requirement of not more than 2.0 %. 
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3.2.3 BIAS, SENSITIVITY AND LINEARITY 
Method bias, sensitivity and linearity tests were performed by means of linear 
regression analysis. A calibration curve was constructed by plotting the peak area of 
each active component versus the concentration of the respective active. The in-
house requirement for linearity is that the correlation coefficient (R) of the regression 
line must be greater than 0.99. An R-value of > 0.99 does, however, does not 
automatically mean that the calibration curve is undeniably linear. To prove linearity 
unequivocally, more robust statistical tests for linearity need to be performed. This 
involves fitting a quadratic curve to the data sets and then testing by using a standard 
t-test whether the coefficient associated with the quadratic term is zero or not. 
The general quadratic equation fitted to each set of calibration data for the three 
active substances is: 
A = β0 + β1C + β2C2 + ε [3.1] 
 
Where A = observed area in absorbance units (AU) 
 C = observed concentration in mg/mL 
β0, β1 and β2 are the estimated model coefficients 
ε = the error variation. 
 
Equation 3.1 can be used to test three properties of the calibration curve, namely: 
1. Systematic error (bias). The presence, or not, of systematic error can be 
evaluated by testing whether the experimentally determined intercept, β0, 
differs significantly from zero or not.  The degree of systematic error is 
assessed by expressing the y-intercept as a percentage of the detector 
response at the 100 % concentration level; this value generally known as the 
z-value. The z-value is given by Equation 3.2. 
 
														z	value=
y	intercept
concentration	of	active	at	100	%	working	concentration	
×100 
                     [3.2] 
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The formal null hypothesis for this test is given by H0: z - value = ± 5.0%. The 
alternative hypothesis, Ha, is therefore Ha≠ ± 5.0%. The intercept is not forced 
through zero hence it can either be positive or negative depending where on 
the y axis it falls. Literature suggested that this z-value should normally fall 
within the range of - 2.0 to + 2.0 for the validation to be accurate.61  
This approach and limits are typically used for assay methods. Dissolution 
methods are regarded as semi-quantitative methods for testing the rate of drug 
release, resulting in larger margins of error. Furthermore the requirements for 
accuracy and method precision for dissolution methods are 5.0% where as 
those for an assay method is 2.0 % respectively, for both % recovery and % 
RSD. Therefore for dissolution the z-value should lie between +5 and – 5.  
 
2. Sensitivity: The test for sensitivity is performed by testing whether the 
experimentally determined gradient, β1, differs significantly from zero or not. 
The formal null hypothesis for this test is given by H1: β1 = 0. The alternative 
hypothesis is that Ha1: β1 ≠ 0  
 
3. Linearity: The linearity, or non-linearity, of the calibration curve is evaluated by 
testing whether the experimentally determined coefficient of the quadratic term, 
β2, is equal to zero or not. The formal null hypothesis for this test is given by 
H2: β2 = 0. The alternative hypothesis is that Ha2: βa2 ≠ 0  
 
The acceptance/rejection of the formal null hypotheses discussed above depends on 
the magnitude of the p-value associated with the null hypothesis. Generally the 
smaller the p-value the bigger the chance that the alternative hypothesis is true. 
Interpretation of p-values can be summarized as follows;62 
• If p < 0.01 there is very strong evidence against H0, i.e. Ha should be 
accepted. 
• 0.01 ≤ p < 0.05 there is moderate evidence against H0; Ha is generally 
accepted. 
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• 0.05 ≤ p < 0.10 although there is suggestive evidence against H0, H0 
cannot be rejected. 
• 0.10 ≤ p there is little or no real evidence against H0, and H0 is accepted. 
 
It is also possible to estimate the uncertainty associated with a calibration curve by 
means of Equation. [3.3]. 
Uncertainty =	

 	 ∙    [3.3] 
Where α = 0.05 (95 % confidence interval, CI) 
t = table value for n – 2 degrees of freedom  
 
	= the error associated with the calibration curve, and is given by Equation [3.4]. 
  
 
 
                                                                                                 [3.4] 
 
Where  
b1 = is the slope of the line 
r = the number of replicate unknowns 
n = the number of standards used in the calibration curve (including the blank) 
0Y  = the actual observed signals related to the standard concentrations 
Y = the average measurements of the standards 
iX = the actual observed concentration 
X
 
= the average concentration of the standards 
eS  = is the error associated with the calibration curve, and is given by Equation 3.5 
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                            [3.5] 
 
Where = predicted observation according to the calibration curve  
  = the actual observed signal signals related to the standard concentrations 
n = the number of standards used in the calibration curve (including the blank). 
 
 The UPLC chromatographic results for the standard curve analysis for paracetamol 
are summarised in Table 3.7 and the results of the regression analysis, which was 
performed using Microsoft Excel, in Table 3.8 (a) and Table 3.8 (b). 
 
Table 3.7:  Calibration data for paracetamol – Range: 0.035 to 0.42 mg/mL 
% paracetamol Theoretical concentration (mg/mL) Peak area (AU) 
0 0 0 
10 0.03548 215734 
20 0.07096 429321 
30 0.1065 632983 
40 0.1419 843900 
50 0.1774 1049556 
60 0.2129 1258900 
70 0.2484 1480168 
80 0.2839 1676595 
90 0.3193 1851169 
100 0.3548 2067026 
110 0.3903 2273388 
120 0.4258 2481966 
 
  
2
1
ˆ( )
n
i i
i
Se Y Y
=
= −∑
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Table 3.8 a:  Results of the Regression analysis for the linear calibration curve for 
Paracetamol. 
Factor Coefficient Estimate Standard Error t-Value Prob > |t| 
Intercept (β0) 15137.90 6180.47 2.44 0.32 
Concentration 
(β1) 5804191.76 24633.40 235.62 1.01 x 10
-21
 
R > 0.99 
ANOVA 
Source of 
Variation 
Degrees of 
Freedom 
Error Sum of 
Squares 
Mean 
Square F-Value Prob > |F| 
Intercept 1 7.72 x 1012 3.86 x 1012 5.55 x 104 1.01 x 10-21 
Residual 11 1.5 x 109 1.39 x 108   
Total 12 7.72 x 1012    
 
Table 3.8 b:  Results of the Regression analysis for the quadratic calibration curve 
for Paracetamol. 
 
Factor Coefficient Estimate Standard Error t-Value Prob > |t| 
Intercept (β0) 2408.42 6661.28 0.36 0.72 
Concentration 
(β1) 5999873.97 72684.03 82.55 1.66 x 10
-15
 
[Concentration]2 
(β11) -459578.97 164536.31 -2.79 0.019 
R > 0.99 
ANOVA 
Source of 
Variation 
Degrees of 
Freedom 
Error Sum of 
Squares 
Mean 
Square F-Value Prob > |F| 
Intercept 2 7.72 x 1012 3.86 x 1012 4.49 x 104 1.70 x 10-20 
Residual 10 8.59 x 108 8.59 x 108   
Total 12 7.72 x 1012    
 
 
CONFIDENTIAL INTELLECTUAL PROPERTY OF ASPEN PHARMACARE Page 65 
 
 
 
Figure 3.5  Calibration curve for paracetamol 
Using the results summarized above for the paracetamol calibration curve, bias, 
sensitivity and linearity may be evaluated. 
1. Systematic error: Using Eqn (3.2) and the β0-value obtained from the 
linear regression line we find that the
 
z-value = 0.73 %. This value is < 
5.0%, which means that the null hypothesis is accepted, and no systematic 
error can be detected as the y-intercept does not differ significantly from 
zero. 
 
2. Sensitivity: The hypothesis that β1 = 0, must be rejected in view of the very 
small p-value (<0.0001) associated with (β1) which indicates that the true 
gradient is >0, hence the instrument is indeed sensitive to changes in the 
concentration.  
  
y = 5.80 x 106 x + 1.5 x104
R = 0.99
0
500000
1000000
1500000
2000000
2500000
3000000
0 0.05 0.1 0.15 0.2 0.25 0.3 0.35 0.4 0.45
Av
er
ag
e 
Ar
ea
 
(A
U)
Concentration (mg /ml)
CONFIDENTIAL INTELLECTUAL PROPERTY OF ASPEN PHARMACARE Page 66 
 
 
3. Linearity: The quadratic regression analysis indicate that there is some 
evidence of curvature in the calibration curve since the p-value of the 
quadratic coefficient, β2, = 0.01901. However, the linear model predicts all 
the values in the range 95 – 105% (Table 3.9) of the actual values, which 
indicates that the curvature is too small to have a practical influence on the 
results. The null hypothesis can therefore be accepted that the instrument 
does not show any curvature and the nature of the relationship is linear. 
 
Table 3.9:  Linear model predictions 
 
% 
paracetamol 
Theoretical 
concentration 
(mg/mL) 
Peak area 
(AU) 
Predicted 
concentration 
(mg/mL) 
Recovery (%) 
0 0 0 -0.00261 - 
10 0.03548 215734 0.034561 97.41% 
20 0.07096 429321 0.071359 100.56% 
30 0.1065 632983 0.106448 99.95% 
40 0.1419 843900 0.142787 100.62% 
50 0.1774 1049556 0.178219 100.46% 
60 0.2129 1258900 0.214287 100.65% 
70 0.2484 1480168 0.252409 101.61% 
80 0.2839 1676595 0.286251 100.83% 
90 0.3193 1851169 0.316328 99.07% 
100 0.3548 2067026 0.353518 99.64% 
110 0.3903 2273388 0.389072 99.69% 
120 0.4258 2481966 0.425008 99.81% 
 
Using Eqn 3.3, the uncertainty associated with the calibration curve was calculated to 
be ± 0.051 or 2.4 % at a Y-value of 1258900. 
The UPLC chromatographic results for the standard curve analysis for caffeine are 
summarised in Table 3.10 and the results of the regression analysis, which was 
performed using Microsoft Excel, in Table 3.11 (a) and Table 3.11 (b). 
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Table 3.10: Calibration data for caffeine – Range: 0.0035 to 0.042 mg/mL 
 
 
 
 
 
 
 
 
 
 
Table 3.11 a:  Results of the Regression analysis for the linear calibration curve for 
Caffeine 
Factor Coefficient Estimate Standard Error t-Value Prob > |t| 
Intercept (β0) 504.58 699.56 0.72 0.49 
Concentration 
(β1) 7.21 x10
6 27901.21 258.25 3.68 x 10-22 
R > 0.99 
ANOVA 
Source of 
Variation 
Degrees of 
Freedom 
Error Sum of 
Squares 
Mean 
Square F-Value Prob > |F| 
Intercept 1 1.188 x 1011 1.19 x 1011 6.66 x 104 3.68 x 10-22 
Residual 11 1.96 x 107 1.78 x 106   
Total 12 1.19 x 1011    
 
 
 
 
% caffeine 
Theoretical 
concentration 
(mg/mL) 
Concentration 2 average area (AU) 
0 0 0 0 
10 0.003546 0.00001257 25309 
20 0.007092 0.00005030 50643 
30 0.01064 0.0001132 77805 
40 0.01418 0.0002011 104142 
50 0.01773 0.0003144 129319 
60 0.02128 0.0004528 154074 
70 0.02482 0.0006160 180572 
80 0.02837 0.0008049 205728 
90 0.03191 0.001018 227774 
100 0.03546 0.001257 254353 
110 0.03900 0.001521 281217 
120 0.04255 0.001811 308538 
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Table 3.11 b:  Results of the Regression analysis for the quadratic calibration curve 
for Caffeine. 
 
Factor Coefficient Estimate Standard Error t-Value Prob > |t| 
Intercept (β0) 45.28 983.34 0.46 0.96 
Concentration 
(β1) 7.27 x 10
6 1.07 x 105 67.77 1.19 x 10-14 
[Concentration]2 
(β11) -1.66 x 10
7
 2.43 x 106 -0.068 0.51 
R > 0.99 
ANOVA 
Source of 
Variation 
Degrees of 
Freedom 
Error Sum of 
Squares 
Mean 
Square F-Value Prob > |F| 
Intercept 2 1.18 x 1011 5.94 x 1011 3.17 x 104 9.71 x 10-20 
Residual 10 1.87 x 107 1.87 x 107   
Total 12 1.18 x 1011    
 
 
 
Figure 3.6:  Calibration curve for caffeine 
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The statistical results for caffeine using equation 3.1: 
1. Systematic error; using Eqn (3.2) and the β0-value obtained from the 
linear regression line we find that the z-value= 0.2 %. This value is < 5.0%, 
which means that the null hypothesis is accepted, and no systematic error 
can be detected as the y-intercept does not differ significantly from zero. 
 
2. Sensitivity: The hypothesis that β1 = 0, must be rejected in view of the very 
small p-value (<0.00001) associated with (β1) which indicates that the true 
gradient is > 0, hence the instrument is indeed sensitive to changes in the 
concentration.  
 
3. Linearity: The quadratic regression analysis indicates that there is no 
evidence of curvature in the calibration curve since the p-value of the 
quadratic coefficient, β2, = 0.51.The null hypothesis can therefore be 
accepted that the instrument does not show any curvature and the nature of 
the relationship is linear. 
 
Using Eqn 3.3, the uncertainty associated with the calibration curve was calculated to 
be ± 0.005 or 2.0 % when Y0, the intercept = 1180572 
The UPLC chromatographic results for the standard curve analysis for codeine 
phosphate are summarised in Table 3.12 and the results of the regression analysis, 
which was performed using Microsoft Excel, in Table 3.13 (a) and Table 3.13 (b). 
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Table 3.12:  Calibration data for codeine phosphate – Range: 0.009 to 0.010 
mg/mL 
% codeine 
phosphate 
Theoretical concentration 
(mg/mL) Concentration 
2
 average area(AU) 
0 0 0 0 
10 0.000888 0.0000007885 7174 
20 0.001775 0.000003151 12271 
30 0.002663 0.000007092 17408 
40 0.00355 0.00001260 22429 
50 0.004438 0.00001970 28092 
60 0.005326 0.00002837 33103 
70 0.006213 0.00003860 38630 
80 0.007101 0.00005042 43794 
90 0.007988 0.00006381 48330 
100 0.008876 0.00007878 53856 
110 0.009764 0.00009534 59811 
120 0.01065 0.00011342 65784 
 
Table 3.13 a:  Results of the Regression analysis for the linear calibration curve for 
Codeine phosphate 
Factor Coefficient Estimate Standard Error t-Value Prob > |t| 
Intercept (β0) 1141.64 301.53 3.78 0.0030 
Concentration 
(β1) 6.00 x10
6 48043.47 125.02 1.07 x 10-18 
R > 0.99 
ANOVA 
Source of 
Variation 
Degrees of 
Freedom 
Error Sum of 
Squares 
Mean 
Square F-Value Prob > |F| 
Intercept 1 5.17 x 109 2.59 x 109 15630.45 1.07 x 10-18 
Residual 11 3.63 x 106 3.31 x 105   
Total 12 5.18 x 109    
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Table 3.13 b:  Results of the Regression analysis for the quadratic calibration curve 
for Codeine phosphate. 
Factor Coefficient Estimate Standard Error t-Value Prob > |t| 
Intercept (β0) 1083.23 432.79 2.50 0.031 
Concentration 
(β1) 6.04 x 10
6 1.89 x 105 32.00 2.09 x 10--11 
[Concentration]2 
(β11) -3.37 x 10
6
 1.71 x 107 -0.20 0.84 
R > 0.99 
ANOVA 
Source of 
Variation 
Degrees of 
Freedom 
Error Sum of 
Squares 
Mean 
Square F-Value Prob > |F| 
Intercept 2 1.18 x 1011 5.94 x 1011 3.17 x 104 9.71 x 10-20 
Residual 10 1.87 x 107 1.87 x 107   
Total 12 1.18 x 1011    
 
 
Figure 3.7:  Calibration curve for codeine phosphate 
The statistical results for caffeine using equation 3.1: 
1. Systematic error; using Eqn (3.2) and the β0-value obtained from the 
linear regression line we find that the z-value= 2.1 %. This value is < 5.0%, 
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which means that the null hypothesis is accepted, and no systematic error 
can be detected as the y-intercept does not differ significantly from zero. 
 
2. Sensitivity: The hypothesis that β1 = 0, must be rejected in view of the very 
small p-value (<0.00001) associated with (β1) which indicates that the true 
gradient is >0, hence the instrument is indeed sensitive to changes in the 
concentration.  
 
3. Linearity: The quadratic regression analysis indicates that there is no 
evidence of curvature in the calibration curve since the p-value of the 
quadratic coefficient, β2, = 0.84.The null hypothesis can therefore be 
accepted that the instrument does not show any curvature and the nature of 
the relationship is linear. 
 
Using Eqn 3.3, the uncertainty associated with the calibration curve was calculated to 
be ± 0.0002 or 3.2 % when Y0, the intercept = 38630. 
3.2.4 ACCURACY 
Method accuracy was estimated by evaluating the closeness of agreement between 
observed and the true values for analytical samples containing between 10 to 120% 
of the amount of the respective active in finished product. The “true” amount is taken 
as the amount of each active actually weighed out, while the actual amount is the 
amount determined by the instrument based on a calibration curve. The percentage 
recovery for these determinations must be within 95.0-105.0 % with a % Relative Bias 
(error) of less than 5.0 %, respectively. 
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Table 3.14:  Percentage recovery for paracetamol 
Conc. 
[%] 
True Amount 
(mg/mL) 
(T) 
Actual 
Amount 
(mg/mL) 
(A) 
% Recovery Bias=A-T % Relative Bias 
10 0.03543 0.03618 102.0% 0.00075 2.12 
20 0.07086 0.07213 101.8% 0.00127 1.79 
50 0.1771 0.1791 101.1% 0.002 1.13 
80 0.2834 0.2798 98.7% -0.0036 -1.27 
100 0.3543 0.3497 98.7% -0.0046 -1.30 
120 0.4251 0.4209 99.0% -0.0042 -0.99 
 
Table 3.15: Percentage recovery for caffeine 
Conc. 
[%] 
True Amount 
(mg/mL) 
(T) 
Actual Amount 
(mg/mL) 
(A) 
% Recovery Bias=A-T % Relative Bias 
10 0.003591 0.003596 100.10% 0.000005 0.14 
20 0.007183 0.007222 100.50% 0.000039 0.54 
50 0.01796 0.01798 100.10% 0.000020 0.11 
80 0.02873 0.0284 98.90% -0.000330 -1.15 
100 0.03591 0.03572 99.50% -0.000190 -0.53 
120 0.0431 0.04334 100.60% 0.000240 0.56 
 
Table 3.16  Percentage recovery for codeine phosphate 
Conc. 
[%] 
True Amount 
(mg/mL) 
(T) 
Actual Amount 
(mg/mL) 
(A) 
% Recovery Bias=A-T % Relative Bias 
10 0.008899 -* - *% *- *- 
20 0.00178 0.001663 93.40% -0.000117 -6.57 
50 0.00445 0.004367 97.00% -0.000083 -1.87 
80 0.00712 0.00702 98.60% -0.000100 -1.40 
100 0.008899 0.008769 98.50% -0.000130 -1.46 
120 0.01068 0.01078 100.90% 0.000100 0.94 
*Peak was too small to integrate and quantify accurately  
The percentage recoveries for paracetamol and caffeine falls within the acceptance 
criteria (95 – 105 %), but the percentage recovery for codeine phosphate only meet 
these criteria within the range of 50 – 120 % of the 100 % working concentration, The 
smaller working range (see later) for codeine phosphate is due, in part, to its lower 
working concentration, and in part to its low absorbance at 220 nm.   
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The control charts (Figures 3.8
upper specification limit (UCL) and lower specification 
For codeine phosphate the control chart highlights the second sample as an outlier 
below the lower specification limit.
Figure 3.8: Control chart for paracetamol
Figure 3.9:  Control chart for caffeine
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Figure 3.10:  Control chart for codeine phosphate.
Note: at 
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3.2.5.1 Repeatability: 
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Table 3.17:   Repeatability data obtained for the three respective actives of product 
X 
Product X - UPLC Dissolution Repeatability 
Sample No. Paracetamol (%) Caffeine (%) Codeine phosphate (%) 
1 96.6 94.3 94.8 
2 96.7 95.5 96.5 
3 96.6 95.4 95.5 
4 96.3 96.7 92.1 
5 96.6 100.5 95.0 
6 96.7 102.0 98.5 
Mean 96.6 97.4 95.4 
Standard Deviation 0.15 3.11 2.11 
Relative Standard 
Deviation (% RSD) 0.15 3.20 2.21 
Confidence Interval 0.15 3.3 2.2 
 
The % RSD of the six replicate samples meets the acceptance criteria of less than 
5.0% RSD. 
3.2.5.2 Reproducibility: 
Table 3.18:  Inter-laboratory analysis of six replicate samples of Product X 
Product X - UPLC Dissolution Reproducibility 
 
Paracetamol (%) Caffeine (%) Codeine phosphate (%) 
Sample No. Analyst 1 Analyst 2 Analyst 1 Analyst 2 Analyst 1 Analyst 2 
1 96.6 98.5 94.3 94.3 94.8 100.5 
2 96.7 97.3 95.5 95.5 96.5 97.0 
3 96.6 97.5 95.4 95.4 95.5 97.7 
4 96.3 96.7 96.7 96.7 92.1 94.8 
5 96.6 96.7 100.5 100.5 95.0 99.2 
6 96.7 96.7 102.0 102.0 98.5 99.3 
   
Mean 96.6 97.2 97.4 97.4 95.4 98.1 
Standard deviation 0.15 0.71 3.11 3.11 2.11 2.03 
Relative standard 
deviation (% RSD) 0.15 0.73 3.20 3.20 2.21 2.07 
Confidence interval 0.15 0.71 3.3 4.5 2.2 2.7 
P(T<=t) two - tail 0.053 0.25 0.048 
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The % RSD’s of the six inter-laboratory samples are all within the acceptance criteria 
for method validation. 
The reproducibility results were further analysed by means of a t-test for two samples 
assuming equal variances. The null hypothesis is Ho: µAnalyst 1= µAnalyst 2 and the 
alternative hypothesis, Ha: µAnalyst 1≠ µAnalyst 2.The estimated t-values and their 
corresponding p-values are given in Table 3.13. 
For caffeine the hypothesis is accepted (p = 0.25), as there is no evidence of a 
difference between the average results of analyst 1 and analyst 2 and the observed 
difference between sample means can be explained in terms of normal experimental 
error. For paracetamol and caffeine the hypothesis is also accepted despite the fact 
that there is some weak evidence that analyst 1 is doing something different from 
analyst 2. 
3.2.6 RANGE 
The results obtained for the linearity and accuracy tests indicate that the respective 
valid analytical ranges for the three actives are: 
Paracetamol: 0.035 mg/mL to 0.43 mg/mL, representing 10 % to 120 %. 
Caffeine: 0.035 mg/mL to 0.043 mg/mL, representing 10 % to 120 %.Codeine 
phosphate: 0.045 mg/mL to 0.0108 mg/mL, representing 50% to 120 %. 
3.2.7 STABILITY OF SOLUTION 
The stability of the standard and sample solutions were evaluated over a 48 hour 
period by estimating the percentage (%) loss of active substance from the time of 
preparation of the respective solution. The evaluations were carried out under 
ambient (25 ºC) and refrigerated (4 ºC) conditions by taking the initial response (peak 
area at time 0) as 100 %. The results obtained are summarised in Table 3.14. 
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Table 3.19:  Stability of solution data at ambient and refrigerated conditions 
  Ambient temperature 25 ºC Fridge 4ºC 
Time 
(H) 
Mass  (mg) Area Response 
(AU) 
% loss Area Response 
(AU) 
% loss 
paracetamol  standard 
    
0 712.36 2059295 
 
2059295 
 
8 712.02 2049554 0.4 2053829 0.3 
24 710.69 2050593 0.2 2071552 -0.8 
48 711.99 20727033 1.5 2059788 0.0 
paracetamol sample 
    
0 640.6 2034884 
 
2034884 
 
8 640.6 2024818 0.5 2027300 0.4 
24 640.8 2030927 0.2 2031387 0.2 
48 640.4 1994745 1.9 2019966 0.7 
caffeine standard 
    
0 72.22 253406 
 
253406 
 
8 71.26 250438 -0.2 250438 -0.2 
24 71.97 255048 -0.1 255596 -1.2 
48 71.53 252465 -0.6 251616 -0.3 
caffeine standard 
    
0 640.6 257131 
 
257131 
 
8 640.2 252699 1.7 250353 2.6 
24 640.4 251144 0 250369 2.6 
48 640.4 247310 -0.1 247363 3.8 
codeine phosphate 
standard 
    
0 90.14 51709 
 
51709 
 
8 90.85 52779 -1.3 51763 0.7 
24 91.37 51337 2.1 53102 -1.3 
48 90.76 51883 0.3 518115 0.5 
codeine phosphate sample 
    
0 640.6 51206 
 
51206 
 
8 640.2 50908 0.6 49969 2.0 
24 640.4 51139 0.2 51607 -0.8 
48 640.4 50478 1.4 50373 1.6 
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From the above data and the requirements given in chapters one and two, the 
requirements for stability of solution were met as the assay results showed that no 
loss of active occurred, (% loss < 5.0) in the standard and sample solutions while 
standing for the maximum time period of 48 hours. No degradation product peaks 
could be observed. 
3.2.8 MOBILE PHASE SHELF LIFE 
The system suitability results obtained from the mobile phase after standing for 7 
days was compared to the initial system suitability results obtained at the beginning of 
the validation. The requirements were still met even after 7 days and no signs of 
cloudiness and precipitation of the mobile phase were noted. It can therefore be 
concluded that the mobile phase is stable for 7 days. 
3.2.9 ROBUSTNESS 
Robustness measures the capacity of the analytical procedure to remain unaffected 
by small, but deliberate variations in procedural parameters.  
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Table 3.20:  Robustness data shows the effects of the changes in analytical 
conditions for Paracetamol 
CONDITION RT (min) Area (AU) N Tang Tailing 
 
% RSD 
Pass / Fail 
System 
suitability 
INITIAL 0.5 2081306 3615 1.3 0.77 Pass 
Different batch of 
column 
0.5 1774697 3781 1.6 0.94 Pass 
Mobile phase* 
(85:15) 0.4 1955646 3358 1.4 0.76 
Fail 
(Rs < 4.0) 
Mobile phase* 
(95:5) 1.0 2172020 4521 1.3 0.63 Pass 
Column 
temperature 35°C 
0.5 2027918 3953 1.3 0.64 Pass 
Column 
temperature 45°C 
0.5 
 
2023454 3897 1.3 0.48 Pass 
Flow rate 
0.55 mL / min 
0.6 2394885 4055 1.3 0.5 Pass 
Flow rate 
0.75 mL/min 
0.4 1751958 3597 1.3 0.26 Pass 
*Mobile phase = Water (containing 0.15% TFA)/Acetonitrile 
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Table 3.21  Robustness data shows the effects of the changes in analytical 
conditions for Caffeine 
CONDITION RT (min) Area (AU) N Tang Tailing 
 
% RSD 
Pass / Fail 
System 
suitability 
INITIAL 1.0 254819 4853 1.2 0.80 Pass 
Different batch 
of column 
0.9 249414 6912 1.3 0.97 Pass 
Mobile phase* 
(85:15) 0.5 240956 4275 1.3 1.34 
Fail 
(Rs < 4.0) 
Mobile phase* 
(95:5) 3.3 248570 5316 1.2 0.67 Pass 
Column 
temperature 
35°C 
1.0 243806 4883 1.2 0.75 Pass 
Column 
temperature 
45°C 
0.9 245818 5016 1.2 0.63 Pass 
Flow rate 
0.55 mL / min 
1.1 291983 5388 1.2 0.60 Pass 
Flow rate 
0.75 mL / min 
0.8 212181 4729 1.2 0.62 Pass 
*Mobile phase = Water (containing 0.15% TFA)/Acetonitrile 
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Table 3.22:  Robustness data shows the effects of the changes in analytical 
conditions for Codeine phosphate  
CONDITION 
RT 
(min) Area (AU) N Tang Tailing % RSD 
Pass / Fail 
System 
suitability 
INITIAL 1.4 54616 4791 1.1 1.6 Pass 
Different batch 
of column 
1.3 52193 6654 1.2 1.2 Pass 
Mobile phase** 
(85:15) 0.6 51991 4026 1.3 0.5 
Fail 
(Rs < 4.0) 
Mobile phase** 
(95:5) 5.2 40317 7139 1.1 1.4 Pass 
Column 
temperature 
35°C 
1.4 49685 4913 1.2 2.8 
Fail 
(RSD >2.0) 
Column 
temperature 
45°C 
1.4 49162 5115 1.2 1.5 Pass 
Flow rate 
0.55 mL / min 
1.6 59217 5635 1.1 0.9 Pass 
Flow rate 
0.75 mL / min 
1.2 43748 4506 1.2 1.0 Pass 
* = Resolution; **Mobile phase = Water (containing 0.15% TFA)/Acetonitrile 
The results summarised above indicate that the method fails when: (a) The mobile 
phase ratio is reduced to 85 % (water/TFA): 15 % acetonitrile since the peak 
resolution between caffeine and codeine phosphate is decreased (Rs < 4.0); and (b) 
When the column temperature is reduced to 35 oC. These preliminary findings 
suggest that system conditions would need to be controlled within reasonably narrow 
ranges. These ranges would need to be established carefully by more 
experimentation. 
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3.3 APPLICATION OF THE DEVELOPED UPLC METHOD ON 
PRODUCTS Y AND Z  
The primary aim of this part of the investigation was to evaluate whether the UPLC 
method can also be used for the analysis of dissolution samples for products Y and Z 
which contained an antihistamine component (diphenhydramine HCl) in addition to 
the three actives in Product X. 
Further, if the results indicate that the method could not be used directly (as is defined 
in Table 3.3), the aim was to establish which modifications could / should be made so 
that the resulting method can be validated separately for Products Y and Z. The 
amounts of paracetamol, caffeine, and codeine phosphate in Products Y and Z are 
compared to the respective amounts in Product X in Table 3.18. The relatively large 
variation in the amount of paracetamol between the three products may cause 
problems when it comes to selecting a desired injection volume. 
Table 3.23:  Varying ratios of each component in Product X, Product Y and Product 
Z 
 Product X Product Y Product Z 
Paracetamol (% m/m) 5032 4057 4574 
Caffeine (% m/m) 53.2 56 3.65 
Codeine phosphate (% m/m) 12 12 12 
 
The elution time of the antihistamine component in product Y was first established for 
the UPLC method derived in the preceding sections. No peak for diphenhydramine 
HCl standard was, however, detected by direct application of this method, but by 
extending the total runtime to 30 minutes, the peak due to diphenhydramine HCl 
could be observed at 22 minutes. To establish whether an increase in the percentage 
acetonitrile in the mobile phase would hasten the elution of Diphenhydramine HCl, a 
gradient run was performed in which acetonitrile was increased from 10 % to 90 %. 
The gradient profile used for this evaluation is given in Table 3.23. 
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Table 3.24: Gradient profile for the elution of diphenhydramine HCl
 Time (min)  
1 0 min 
2 0 - 10 min 
3 10 - 20 min 
4 20 - 21 min  
5 21 – 25 min  
* A = water containing 0.15 % TFA
Under the above gradient conditions, d
shown in Figure 3.11. 
Figure 3.11:  Chromatogram 
Tables 3.3 and Table 3.24
The percentage acetonitrile
= 80 % in 10 minutes; equivalent to an 8 % change in 1 minute
conducted using an initial 
allow for the elution of paracetamol, caffeine and codeine phosphate
gradient change to 30 % 
Under these conditions (Table 3.3 and Table 3.24)
minutes for both a standard solution 
 
Flow Rate  %A* 
0.650 90.0 
0.650 10.0 
0.650 10.0 
0.650 90.0 
0.650 90.0 
; ** B = acetonitrile. 
iphenhydramine HCl eluted at 3.2 min as 
for diphenhydramine HCl under gradient elution
 
 in the mobile phase at 3.2 minutes is about 25
). 
mobile phase ratio of 90 % A : 10 % 
acetonitrile to allow for the elution of diphenhydramine 
 diphenhydramine
(Figure 3.12) and a sample solution
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%B** 
10.0 
90.0 
90.0 
10.0 
10.0 
 
, as per 
 % (90 – 10 
An analysis run was 
B for 1.6 minutes to 
, followed by a 
HCl.  
 HCl eluted at 2.8 
 (Figure 
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3.13). All components were separated 
differed from the Gaussian ideal. Significant 
and sample chromatograms.
Figure 3.12:  Chromatogram for diphenhydramine
Figure 3.13:  Chromatogram
To test system suitability of the method 
made of Product Y sample solution.
 
 
by this method; however
tailing was observed in both the standard 
 
 HCl standard solution
 for Product Y using gradient elution
for Product Y, two replicate injections were 
 
Page 85 
 the peak shape 
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Table 3.25:  System suitability for Method Y  
Injection 
number 
Peak response in 
area 
Peak response in 
area 
Peak response in 
area 
Peak response in 
area 
 Paracetamol Caffeine 
Codeine 
Phosphate 
Diphenhydramine 
HCL 
1 5002408 1241312 172445 73358 
2 4951845 1241873 176124 70942 
  
Mean 2081306 254819 54616 72150 
SD 16067.3 2026.9 846.8 1708.4 
% RSD 0.8 0.8 1.6 2.4 
Peak Tailing 1.3 1.4 1.5 1.5 
Plate count 2259 4362 3798 21316 
 
The estimated % RSD’s were 0.1 % for paracetamol, 0.5 % for caffeine, and 1.6 % for 
codeine phosphate. The retention factor k’1 was 1.93, Tf < = 1.5 was obtained for all 
components. The theoretical plate count per 5 cm was found to be approximately 
2259 for paracetamol, which is less than the limit of 3000 theoretical plates per 5 cm. 
This method was found to be inconsistent hence not suitable. 
In order to evaluate the use of the UPLC method for Product X for the analysis of 
dissolution samples of Product Z, the elution time of the antihistamine component 
(doxylamine succinate) in Product Z was first established by injecting a doxylamine 
standard and a Product Z sample solution. Using the analytical conditions for Product 
X directly, doxylamine succinate eluted at 1.29 minutes (Figure 3.14), together with 
codeine phosphate (Figure 3.16).  
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Figure 3.14: Chromatogram 
Figure 3.15:  Chromatogram
Inspection of the PDA data confirmed the co
doxylamine succinate (Figure 3.1
apex at 1.32 minutes indicating another componen
phosphate peak. A rise of purity angle above the noise or threshold angle plot 
suggests the presence of an impurity.
the analysis of Product Z.
 
for doxylamine succinate standard sol
 for Product Z 
-elution of codeine phosphate and 
6) since the purity angle (in green
t on the shoulder of the codeine 
37
 This method was found to be not suitable for 
 The use of a longer column or a change in mobile phase, 
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addition of a pairing reagent, may allow for better separation however this falls 
outside the scope of this project. 
 
 
 
 
 
 
Figure 3.16: PDA data of the codeine phosphate peak in 
3.4 SUMMARY AND CONCLUDI
The following validation parameters (Chapters 1 and 2) for the UPLC method for the 
simultaneous analysis of paracetamol, caffeine, and codeine phosphate in Product X 
have all been shown to be met:
1. Specificity  
2. System suitability 
3. Linearity 
4. Accuracy 
5. Method Precision 
6. Range 
7. Stability of Solution
8. Mobile phase shelf life.
System robustness has raised some question marks that would require further work 
to define ranges for system conditions more accurately. However, if the system 
conditions are controlled to the levels as specified, it may be concluded that the 
 
 
Product Z
NG REMARKS 
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UPLC method for the simultaneous quantification of paracetamol, caffeine and 
codeine phosphate in Product X meets the criteria for a validated analytical method. 
The UPLC method for the simultaneous analysis of the three actives in Product X did 
not prove to be directly applicable for the simultaneous analysis of four actives in 
Products Y and Z. Even with slight changes in the method, no acceptable analytical 
separation could be achieved. Thus, using the HSS T3 column poor peak shape and 
low plate counts were obtained and the results were not reproducible.  
Sufficient evidence has, however, been obtained to indicate that the development of 
similar UPLC methods (capable of simultaneously analysing the various actives in 
Products Y and Z) may be achieved. Thus, future work could, for example, evaluate 
the use of either a different or longer column than the HSS T3 column used during 
this investigation in order to achieve acceptable peak separations. Alternatively, the 
development and validation of two methods (instead of one) may be considered, for 
example in the case of Product Y two separate methods can be run as follows; 
1. Use the method for product X to separate and quantify paracetamol, caffeine  
and codeine phosphate; and 
2. Use an isocratic method with a mobile phase composition of 75 % water/TFA 
and 25 % acetonitrile for the determination of diphenhydramine HCl. 
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CHAPTER 4: BUSINESS CASE 
Pharmaceutical products may only be released for sale if the product meets all 
physical and chemical release specifications. Reducing the time for such analysis of 
finished products will allow pharmaceutical companies to bring products to the market 
faster, thereby increasing throughput, and at the same time optimizing costs. In this 
business case the overall analysis cost of the existing analytical technology (HPLC) 
for the analysis of the finished Product X will be compared with the potentially faster 
UPLC technology to allow management to decide on an appropriate investment 
strategy on this analytical instrumentation. The comparison will include such issues 
as laboratory time, waste generation and waste disposal, and instrument costs. 
4.1 PARETO ANALYSIS OF ANALYTICAL TIME CONSTRAINTS 
The stages listed below are indicative of the sequence of steps in a typical sample 
testing/analysis procedure: 
 Preparation time 
 Instrument time 
 Processing of data 
 Review of data 
 Final QC approval by management 
Preparation time consists of standard/reference solution preparation and sample 
preparation. For the standard solution, a known amount of reference material (a 
material of known composition and purity) is accurately weighed and prepared at the 
working concentration. Responses are determined from the known standard solution 
to generate a calibration curve. The sample is prepared at the working concentration 
and injected twice. The concentration of the sample is determined by comparing the 
sample response to the standard response of the calibration curve to determine the 
sample concentration accurately. This process can take on average 3 hours. 
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Instrumentation time consist of set-up time, equilibration time, injection and run time. 
The amount of instrument time depends on the number of actives in the sample to be 
analyzed, and can vary up to 24 hours. For the purpose of the present analysis, an 
average amount of 10 hours instrument time will be used. 
Processing and reporting of data consist of an electronic review of raw data from the 
chromatograph. The data is processed and written up according to good laboratory 
practices. The masses, reagent list (a list of chemicals used for the analysis, batch 
number and their expiry dates), instrumentation used, calculations, results, deviations 
and any out of specification results are recorded in the analytical work book. This may 
take an average of 2 hours. 
During the review of data, reports are subjected to a quality check by a second 
person, a laboratory quality representative (LQR), who is impartial to the analysis 
process. Test methods, equipment, reagents and calculations are reviewed against 
the test parameters for correctness. The equipment and reagents used are checked if 
they are within calibration and their expiry dates. Any deviations in the methods are 
reported and the data integrity assessed. If the data integrity is not compromised, the 
report is then sent to the laboratory manager for approval. This is done meticulously 
and on average can take up to 5 hours.  
Final approval by management involves an overall assessment of the following: 
 All the required tests have been completed and the results must meet 
specifications 
 Standard operating procedures (SOPs) have been followed and any deviations 
have been reported and assessed 
 Test results were generated using calibrated and maintained equipment 
 Personnel performing the tests have been trained in the relevant techniques 
and skills. An average of 2 hours can be allocated to this part of analysis time.  
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Figure 4.1:  A typical example of 
time for HPLC analysis
 
Figure 4.1 illustrates the 
process and shows that
total analysis / testing time
Product X is a scheduled multi
prior to release. The cost comparison will evaluate the cost 
house HPLC method versus the developed UPLC method for the analysis for Product 
X. This comparison was performed to determine whether the implementation of the 
UPLC method could result in a reduction of overall analysis time, and the cost 
associated with the change from UPLC to HPLC.
4.2  FINANCIAL ANALYSIS 
The following Table 4.1 illustrates 
and the UPLC instruments.
9%
23%
Analytical time constraints for HPLC 
 
the time taken for each step in during analysis 
 in the Pharmaceutical industry. 
approximated amounts of time for the analytical/testing 
 instrument time can have the largest (45 %) impact of the 
. 
-active analgesic drug and requires multiple test runs 
of running the current in
 
 
the total annual running costs for both the HPLC 
 
14%
45%
9%
Analysis
Preparation time
Instrument time
Review/ reporting of data
Review by LQR
Final Approval
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Table 4.1:  A comparative display of the annual running cost of the HPLC versus UPLC  
No Costing per annum Category HPLC UPLC Comments 
1 Column cost Material R 53,568.75 R 20,884.38 Cost = Column cost x (injections per year / injections per column) 
2 Solvent cost Material R 39,375.00 R 2,559.38 Annual solvent (l) x cost per litre (R175 per litre) 
3 Maintenance cost Machine R 60,000.00 R 84,000.00 2 x PPM kits required per year 
4 Waste disposal cost Material R 2,304.00 R 149.76 Waste cost =  Solvent (l) x waste disposal cost 
5 Total Cost per year  R 155,247.75 R 107,593.51  
6 Total Cost per injection  R 10.35 R 7.17 Ratio of UPLC /HPLC = 1.44 
Information for costing purposes  
7 Run time per year (min)  225000 22500 Run time per year = injection per year x run time  (HPLC = 15 and UPLC 1.5)                  
8 Flow rate per injection  1.00 0.65 Standard flow rates  
 (HPLC = 1.0 mL/min & UPLC = 0.65 mL/min 
9 Solvent  per year (l)  225 14.63 Volume (l) =  [Annual runtime (min) x flow rate (mL/min)]/1000 
10 Injections per column  2000 6000 HPLC = 2000 injections per column & UPLC = 6000 injections per 
column based on current practices 
11 Injections per month 1500   Based on historical data for laboratory in question 
12 Injections per year  15000   Annual injection = injections per month x 10 working months per year 
13 PM kit per year 2 
  2 x PPM kits required per year for both HPLC and UPLC based on 
current practices 
14 Waste cost per l (R10.24 per litre) R 10.24   Waste costs = R256 per 25 litre 
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When comparing the annual running costs associated with both HPLC and the UPLC 
it was found that there is a 44 % cost saving when running the UPLC instrument. This 
is largely due to the following factors:  
 Low solvent consumption, 14.63 liters / year on UPLC versus 225 liters / year 
on HPLC, leading to a low cost in organic solvent R 2,559.38 for UPLC versus 
R 39,375.00 for HPLC 
 Low cost of waste disposal, R 149.76 for UPLC compared to R 2,304.00 for 
HPLC waste, as the amount of waste generated is less due to the shorter run 
times on UPLC. 
These cost saving factors are overshadowed by the higher maintenance cost           
(R 24,000.00) for UPLC per year compared to HPLC. The HPLC column cost are 
slightly more expensive, R 8 375, compared to UPLC columns R 7 142 and the 
column life span is longer for UPLC columns (6000 injections compared to 2000 
injection on HPLC columns). Largely due to the shorter run times associated with the 
UPLC, the opportunity cost of each instrument per year was investigated and the 
results of which is shown in Table 4.2.  
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Table 4.2: Opportunity cost per annum (UPLC versus HPLC) 
No 
Opportunity cost (UPLC vs. HPLC) per 
annum 
HPLC UPLC Comments 
1 Annual number of Batches of Product X for testing 360 360 36 x batches per month for 10 months 
2 
Annual Instrument time (minutes) 5400 540 
Annual batches x run time (minutes)                               
HPLC = 15 minutes, UPLC = 1.5 
minutes 
3 Annual Recovery cost (R) R 1,215,000.00 R 121,500.00 Cost =instrument time x hourly rate 
4 Annual Cost savings (R)   R 1,093,500.00 Savings = HPLC - UPLC 
    
Information for costing purposes 
  
 5 Run time (min) per annum   15 1.5   
 6 Number of minutes per annum 288000     
No of minutes per year = 10 months x 20  
working days x 24 hours x 60 minutes 
 7 Laboratory expense per minute (R)  R 225.00     
Laboratory expense rate based on 
history. 
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From the cost analysis it can be seen that there is a potential cost saving o
R1 063 500.00, due to the shorter run
Therefore there is a potential to analyze 10 times more samples in the same amount 
of time at a lower cost on UPLC. For these savings to be realized the followin
assumptions must be considered:
 Assumption 1:  The factory has the c
batches
 Assumption 2:  The laboratory has the c
and sample) 
 Assumption 3:  Equipment 
Therefore the actual savings will be dependent on how these assumptions can be 
optimally managed. 
Figure 4.2:  A typical example of 
the Pharmaceutical industry
 
Similarly to Figure 4.1, Figure
analytical/testing process when using the UPLC instrument. It demonstrates that
time constraints of instrument time (45%), as highlighted in Figure 4.1, is now
39%
Analytical Time Constraints for UPLC 
RTY OF ASPEN PHARMACARE 
 times associated with the UPLC instrument. 
 
apacity to produce 10 times more 
. 
apacity to prepare solution
for 10 times more batches. 
operates 24 hours per day with no breakdowns
the time taken for each step for 
.  
 4.2 illustrates the approximated amount
23%
8%
15%
15%
Analysis
Preparation time
Instrument time
Review/ reporting of data
Review by LQR
Final Approval
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decreased to 8% using UPLC technology. The instrument time constraint is partially 
absorbed by preparation time (23 %) and review by LQR impact on total analysis / 
testing time. 
4.3 DISCUSSION 
The study has shown that there are advantages of UPLC analysis over HPLC and 
these include: 
1) Cost savings as a result of reduced solvent usage is employed. For UPLC 
analysis smaller volumes of mobile phase is needed for analysis because of 
shorter run times and reduced flow rates. 
2) Cost savings as a result of reduced waste disposal cost due to shorter run 
times. 
3) A column cost saving is seen due to the HPLC column life span being only 2000 
injections  as opposed to 6000 injections for UPLC columns. 
4) A cost increase for maintenance of the UPLC is seen as the instrument is 
sensitive and is performed by an external company. 
The higher maintenance costs that are associated with the UPLC may be curbed by a 
training intervention of the UPLC hardware and training of maintenance staff to 
perform in-house preventative maintenance. 
Based on the time savings of the UPLC, it can be said that one UPLC can replace 
three HPLC’s. A major advantage of UPLC is shorter run time which is critical during 
process optimization of products in that the results are available quicker (10 times) 
allowing quicker decision making. External customers (the factory) can be alerted to 
either problems or the release of a batch on the same day as opposed to three days 
later. 
The outcome of this study has allowed the company to consider conversion of HPLC 
to UPLC technology across all operations with technological benefits. 
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Summarized, the implementation of the UPLC instrument saw a reduction in 
instrument time; from 45 % to 8 % which resulted in the laboratory constraint being 
shifted from instrument time to sample preparation and review of data. These factors 
will have to be managed correctly to realize the full potential of time savings. The 
overall cost per injection of running a UPLC was found to be 44 % cheaper than 
HPLC. This study has shown that UPLC technology helps to reduce these costs and 
investing time in the use of this technology may assist with profit sustainability 
allowing the organization to have a competitive edge. 
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CHAPTER 5: CONCLUSION AND RECOMENDATION 
This study aimed to develop methods using the latest technology, column and 
hardware, to increase sample throughput in a typical quality control laboratory.  
A method for the simultaneous determination of paracetamol, caffeine and codeine 
phosphate was developed using UPLC technology. The UPLC method was more 
efficient than the existing HPLC method.  
The UPLC method was then validated in accordance to ICH and USP guidelines. The 
data generated during validation was interpreted by the use of statistical analysis. 
This method complied with the validation requirements and allowed for the fast, 
accurate quantification of paracetamol, caffeine, codeine phosphate in Product X.     
The application of this UPLC method as a starting point for method development of 
analysis methods for other products containing paracetamol, caffeine, codeine 
phosphate and one extra active ingredient was not an easy task. The low 
concentration of the added component, sample matrix and differences in formulations 
added to the challenges. It was found that direct application of the validated method 
for Product X to the analysis of two other products, Product Y and Z, was not 
successful. A better understanding of pharmacopeial methods and reasoning behind 
individual assay at the maxima was obtained especially with multi – active 
formulations. 
The implementation of the UPLC instrument saw a reduction in instrument time; from 
45 % to 8 % which resulted in the laboratory constraint being shifted from instrument 
time to sample preparation and review of data. These factors will have to be managed 
correctly to realize the full potential of time savings. The overall cost per injection of 
running a UPLC was found to be 44 % cheaper than HPLC. This study has shown 
that UPLC technology helps to reduce these costs and investing time in the use of 
this technology may assist with profit sustainability allowing the organization to have a 
competitive edge. 
  
CONFIDENTIAL INTELLECTUAL PROPERTY OF ASPEN PHARMACARE Page 100 
 
 
The regulatory requirements for the upgrade of analytical methodology for a 
registered drug, in the local market, were discussed in chapter 1. The addition of 
UPLC method as an alternate testing method saw the need for supporting 
documentation. The documentation which needs to prove efficacy, is the analytical 
method validation. The documents would be archived and kept available for future 
inspection. The hypothesis to enhance the chromatographic power of UPLC used in 
the analysis of pharmaceutical products to provide faster analysis times, hence 
increased product throughput rates, and lower operating costs was accepted. These 
advantages were achieved whilst meeting all regulatory requirements for analytical 
methods as required by regulatory bodies. 
  
  
CONFIDENTIAL INTELLECTUAL PROPERTY OF ASPEN PHARMACARE
 
 
APPENDIX 1: SPECIFICITY CHROMATO
Chromatographic conditions as mentioned in Section 3.1
FIGURE 1:  Solution 1 -
FIGURE 2:  Solution 2 -
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; Table 3.3
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FIGURE 3:  Solution 3 -
FIGURE 4:  Solution 4 -
 
 Standard 
 Sample 
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FIGURE 5:  Solution 5 -
FIGURE 6:  Solution 6 -
 
 Paracetamol 
 Caffeine 
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FIGURE 7:  Solution 7 -
FIGURE 8:  Solution 8 -
 
 Codeine Phosphate 
 Combination standard and all known degradation products
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Figure 9:  Solution 9 –
 
 Sample T 24 months 
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Figure 10:  Peak Purity 
 (paracetamol and caffeine)
 
 
plots for drug active at working concentration 
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Figure 11:  Peak Purity plots for 
 (codeine phosphate
Figure 12:  Peak purity plots for 
 (paracetamol and caffeine
 
drug active at working concentration                
)
drug product at working concentration
)  
Page 107 
 
     
  
CONFIDENTIAL INTELLECTUAL PROPERTY OF ASPEN PHARMACARE
 
 
Figure 13:  Peak purity plots for 
 (codeine phosphate) 
 Figure 13:  Peak purity plots for 
 
drug product at working concentration     
Stability Sample (paracetamol and caffeine)
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Figure 15:  Peak purity plots for 
 
 
Stability Sample (codeine phosphate)
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